Most Recently Posted News

A Case of Delayed Gratification

Wed, 01 Feb 2012 10:17:35 -0500

eClinical 2011: Remedies for the Clinical Trials Machine

The Vendor Mark Weinstein (CEO, BioClinica)

February 1, 2011 | BioClinica CEO Mark Weinstein’s career started out at Andersen Consulting before moving to Thomson Healthcare in the early 1990s. He joined Bio-Imaging Technologies in 1997, later rebranding the firm as BioClinica as the company grew and diversified. Weinstein spoke to Bio•IT World chief editor Kevin Davies about his company’s rapid growth in particular and the trends for the eClinical space.

What is behind BioClinica’s recent activity in acquiring various eClinical technology companies?

Weinstein: Providing technology-enabled services for clinical research is a business for mature individuals because it is delayed gratification. Through the years we’ve done quite a few acquisitions based on where we believe the industry is going. We constantly ask: how can we align ourselves to not only take advantage of it now—being a publicly traded company, I can’t disappear for five years and come back on the scene—but also figure out how does that position us for the future?

I’m just amazed—everything we see in terms of patent cliffs, economic issues and big pharma mentality, has been known as long as I’ve been involved with BioClinica, which is 13 years. There was so much excess in so many of these companies, I don’t know of any big pharma that’s made truly substantive changes as far as how they do research. But with that said, they are asking more questions than they ever have before—and they’re the right questions.

BioClinica originally specialized in imaging technology, correct?

In 1997 I heard about Bio-Imaging Technologies, which was a small company getting ready to take off. The FDA was on the front end of accepting non-clinical endpoints to prove that drugs or devices work. But, it wanted the data centrally reviewed. They didn’t want 1,000 radiologists’ opinions for 1,000 patients. In 1997, it was just starting to formalize ideas about how the data were going to be centrally reviewed. Bio-Imaging Technologies was on the front edge of that. We worked with FDA, some of the first submissions were on rheumatoid arthritis (TNF inhibitors), and we were centrally reviewing the images.

While we were strong in musculoskeletal and oncology, I could see pharma using more imaging endpoints across additional therapeutic areas, but they want to work with fewer vendors over time. We made several acquisitions to round out our therapeutic offerings. Ultimately, pharma would want a preferred provider that could service their needs in all therapeutic areas. Therapeutic expertise is absolutely key on the imaging side.

Pharma doesn’t buy from very small companies—they have so much risk in their compounds, they’re not willing to take any vendor risk. We saw that back in the ‘90s. In 2007, we saw CNS disorders taking off—very high value scans, but images come from all over the world that need to be standardized. So we found a small French company with nine employees located in Lyon. Theralys had tremendous knowledge and world-class software. But they couldn’t get a Phase III study from a major pharma, because they were nine people in Lyon, France! We brought them in, made them part of Bio-Imaging Technologies, and suddenly, they’re part of a 300-person company with global reach. That’s now the fastest growing piece of our business.

How did that imaging experience help in other eClinical areas?

What we did in imaging is what we’re looking to do in the clinical technologies area. Imaging is a great space, but that whole area is maybe $350 million. It’s not a bad market if you’re small, privately held, but we’re looking to extend. From a public company’s perspective, we want the next thing.

There is a technology solution for every pharma department. The systems mirror the siloed mindset that is pervasive in large pharma. Somebody might be doing EDC (one of the first systems to take off), others were doing clinical supply optimization, CTMS, etc. You had all these pieces going on. We said, we think this is a big opportunity here that will play out over a number of years. Pharma wants to do things better, but is still buying point solutions, because that’s the way it buys things.

So we set out to find an entry point into the eClinical arena. We saw Phase Forward/Oracle and Medidata as the two 800-pound gorillas that were focused on technology transfer to major pharma. Additionally we saw that all other pharma companies (1,400 or so) were busy evaluating their core competencies and proactively determining what they should and should not be doing internally. Big pharma’s started many years ago and historically had so much money; they’d spend tens of millions of dollars developing software and often never use it! Back in the day, people didn’t even have budgets on the clinical research side, it was like a bottomless pit. But the lack of new blockbuster drugs has forced the entire pharma industry to evaluate how they can do more research for less dollars, which equates to less internal development and more outsourcing.

We think the magic sauce is various technologies with the right services wrapped around it. Pharma wants to own nothing in the end: ‘I don’t want 150-person IT staff, you can do that for me. I want you to show up before a study starts, help me run it, then leave when the study is complete.”

So your next entry point was EDC?

In 2007 we found an EDC company with a twist—Phoenix Data Systems (PDS). There were many companies of that size, but their geographic [location], the fact that they were profitable and that they had a more comprehensive offering than most others in the space (EDC and data management) helped us make the decision. PDS was founded in 1997 and over the years had established an interesting twist by providing data management services off the back of their EDC offering. This was a differentiator and allowed them to grow a $15-million profitable business. Because of their small size, PDS did not have a great deal of market recognition, but by becoming part of a 350-person company, we put PDS on many people’s maps and reduced the risk to pharma for selecting them for projects.

That was the starting point for our venturing beyond medical image management in March 2008. Little did we know the world would change in the fall of 2008. Given the fact that we had money in the bank, no debt and remained profitable, we began looking for other acquisitions approximately six months after the PDS acquisition. As we looked beyond medical image management we realized that we needed to rebrand the company. If we were going to be a global company involved in many aspects of clinical research services, we can’t have a name like Bio-Imaging Technologies, so we renamed the company BioClinica in spring 2009.

What other acquisitions have you made since then?

We’ve made two other acquisitions: The first acquisition was Tourtellotte Solutions (TS). TS had a clinical supply optimization solution and a development group that has gone on to develop our newly-announced IWR [interactive web response] product, Trident. Prior to the acquisition, TS was viewed as one of the industry leaders in clinical supplies distribution and optimization but couldn’t sell a major enterprise-wide IWR solution because of their 40 person size (see, “Vertex Views Trial Supplies,” Bio•IT World, Dec 2006). Within a month of the acquisition, we were sitting in a top 5 pharma executive’s office, talking about what we could do for them.

We have already begun work on our next offering associated with this—Enterprise Demand Aggregator (EDA). This product aggregates clinical supplies across studies, so at the compound level, companies can do the same powerful optimization.

The second acquisition was Transenda. Transenda has a world-class Clinical Trial Management System (CTMS) and once again because of their size, 20 people, had issues with selling into the industry. As part of BioClinica, we have already secured several large contracts for major organizations, both pharmas and CROs. Historically in the CTMS area there have been $1+ million solutions—Impact, Siebel, etc.—but there is nothing credible for small companies. They’ve used some Outlook, Excel spreadsheets, Word, nothing in a controlled environment. Our CTMS solution, which came from Transenda, is “Office-smart”—and you can report the results using Microsoft SharePoint.

Another positive of the Transenda acquisition was the relationship we now have with Microsoft. As a Gold Certified Partner we get a tremendous amount of support from Microsoft from both the technology and marketing perspectives.

Do you try to sell BioClinica as providing a holistic eClinical solution?

The development and selling of a unified solution will be evolution not revolution. At the highest level, you make sure the senior executives know you have a vision, but probably the people you’re selling to don’t care. They have a job and want a specific solution. We view every sale—Optimizer, CTMS, Trident—as “entry points”. If we go in and provide excellent service with that entry point, we’ll get another shot at another part of the business. We currently provide services or technology to 19 of the top 20 pharma companies. This exposure creates a tremendous number of entry points from which to expand our business.

Cephalon is the #43-ranked pharma—they’ve outsourced all their EDC and data management to us. They want a higher mixture of service to technology. Technology by itself becomes commoditized very quickly. The question is how do you wrap services around it? I can offer a service level, because it’s the fabric of my business, that an Oracle or Medidata might have trouble doing.

There are still about 100 companies in the EDC/IWR space, but they’re thinly capitalized; and most don’t grow beyond where they are today. We have an obligation to our shareholders to maximize the long term value of the stock that they own. This obligation forces us to continue to find ways to grow our revenues and profits.

What other niches would you like to expand into?

A couple of other evolving areas. One is patient-reported outcomes (ePRO). While we’re happy with our core offering, my personal vision is that we’ll see more and more post-approval work, signal detection studies. Pharma is more and more sensitive to safety issues in drugs. Pharma wants to know the answers to the question before the Wall Street Journal does. ePRO will morph into acquisition methodology for post-approval studies and signal detection.

Also, safety systems—how do you monitor situations when there are potential safety issues. Currently there are an amazing number of disparate safety systems in the market and trying to make intelligent decisions is very costly and difficult.

What do you see as the positive impact of eClinical research technology on drug pipelines?

The more data you can bring in and make it electronic, the more you can understand relationships between compounds, symptoms, and disease states. A bed of intelligence is being created by all these data. Ultimately, though, my gut feeling is that big pharma will do far less primary research. I think they’re going to buy results. I deal with 19 of the top 20 pharma companies every month, and I watch how fast a small company can get a study up and running—it’s amazing compared to a big pharma, they’re that nimble. Time is money to them. In many ways, big pharma will get more efficient, because they’ll do less research and buy results. That’s a much less expensive way of operating.

When we deal with smaller pharma companies without a commercialized product, they’ll say, ‘I have to get to the end of a Phase II study with my milestones and then someone will buy it from me.’ Big pharma has the network to run global studies. The more work that transitions to smaller pharma will accelerate the number of studies being done, which will increase the probability of success. That’s a different way to look at it.

As an example, we currently work with a large pharma who runs 200 studies per year on an ongoing basis. Most of their studies are small and only last a few weeks. They approached us on how we could help them become more efficient. By utilizing our technology platform and standard forms that we developed with the pharma client, we have had a very positive effect on productivity and efficiency.

What about patient stratification using genomic technologies?

On the science side, we don’t get involved in Phase I studies or early Phase II. Our value comes in larger studies. By having better inclusion/exclusion criteria (results of genomics is one way to do this) statistically powered results should be obtained with less subjects on a per study basis. Fewer subjects should reduce the overall cost and time it takes to conduct a study. We see an interest in that. From a vendor perspective, you need to be the low cost producer to ensure that you can maintain profitability in smaller studies. We do believe this will happen, and pharma won’t conduct nearly as many large, monolithic studies in the future. We are putting a great deal of investment in our operational infrastructure and technologies to ensure that we can be the most efficient partner for pharma in the future.

What geographic trends do you see in clinical trials?

About four years ago, we crossed over so more than 50% subjects are now rest of the world (ROW), outside the United States and Western Europe. That will continue to accelerate, which helps us. It used to be that you could find 500 subjects in the East Coast of the United States for a study. Now, for that same study, to find the same 500 subjects you might need to go to 20-30 countries and hundreds of principal investigators (PIs). It’s easy to find drug naïve populations [in the ROW] and you’re recruiting in developing countries where subjects are being offered world-class health care for free. These trends lead to more PI sites that have less experience in doing clinical research, which means that, as a vendor, we have to make it as easy as possible to work with our systems. The increased geographic dispersion of the studies combined with the fact that 50% of PIs involved in a clinical research project will never run a second study, leads to constant inflow of new PIs that need additional technologies and services. We don’t anticipate these trends to change for the foreseeable future.

Filling in the gaps as Big Pharma downsizes

Mon, 30 Jan 2012 11:34:24 -0500

Bucks software firm manages drug-trial data. And it's hiring.

As posted on www.philly.com

January 29, 2012 | By David Sell, Inquirer Staff Writer

BioClinica Inc. is a bit unusual these days in the region's pharmaceutical industry. It is hiring.

The company creates computer software to read and measure images, such as brain scans of tumors, and to digest the huge amounts of data related to clinical studies that drug companies sponsor.

The company had 522 employees at the end of 2011 and hopes to add 55 by year's end, with most of the current job listings pegged for headquarters in Newtown, Bucks County, and its site in Audubon, Montgomery County.

BioClinica is looking for computer-software folks and those with pharmaceutical or clinical-trials history, but it will also look at recent college graduates with less technical history.

"We do hire a few project managers right out of college," said Peter Benton, a division president at BioClinica. Benton worked in pharmaceuticals for Johnson & Johnson, but also in TRW's automotive sector and for General Electric, after getting a mechanical-engineering degree at Northeastern and a master's degree in business at Wharton. "We want people who want to learn, want to work hard, and are good communicators."

Big pharmaceutical companies are cutting jobs, often from areas that are not so-called core competencies, or in research where profit no longer seems assured.

Pharmaceutical companies often outsource the management of the drug trials to clinical-research organizations (CROs). Either the drug company or the CROs might outsource the software design and data management. BioClinica's largest shareholder is Covance Inc., a multinational CRO based in Princeton.

BioClinica certainly has competitors. Software firm Oracle Corp. has a health-care division and Philadelphia-area offices. So, too, do Medidata Solutions Inc., eResearchTechnology Inc., and Perceptive Informatics Inc.

BioClinica's chief executive officer, Mark Weinstein, said the company's clients had ranged from a six-person start-up to Pfizer Inc., which accounts for 18 percent of BioClinica's business.

"Big Pharma is changing, and small pharma comes and goes," Weinstein said. "At any point in time, we're working with close to 200 companies. But what changed for everybody is the business model. That is the whole issue of sticking to your core competencies and outsourcing everything else. We're saying we have a low-cost alternative to what you used to do in-house, and we come and go as you need our services. Big Pharma has had monolithic organizations with thousands of people and now is saying, 'I want only hundreds of people, but I need the same services, so where do I go?' "

MarketsandMarkets, a research firm, reported this month that the global market for clinical-trial-management software (CTMS) such as BioClinica's was $576 million in 2010, but would increase by a compounded annual growth rate of 14.5 percent from 2011 through 2016.

The U.S. market is growing because of greater need to prove that drugs are safe and more effective than existing treatments.

Pharma executives and their lobbyists often complain about requirements imposed by the U.S. Food and Drug Administration, which is supposed to check for safety and efficacy of products. But BioClinica benefits from such regulation and might do so in countries such as China and India as those nations want drugmakers to tailor products for them, with corresponding regulation.

Benton noted that BioClinica was able to capture images and data in many formats, but that its programs work through Microsoft's Outlook system, which is used in much of the world.

BioClinica, which will report 2011 fourth-quarter and full-year results in February, has acquired smaller firms in recent years.

The stock, which trades on the Nasdaq, closed Friday up 6 cents, or 1.19 percent, at $5.19.

BioClinica reported to the SEC that its revenue in the nine months ended Sept. 30 increased 10.6 percent to $61.5 million, compared with the same period in 2010.

The company took a $1.7 million charge in 2011, in part to pay severance costs for laid-off employees in its Netherlands office. That expense contributed to a decrease in net income from operations of 18.7 percent from the same period the previous year. Absent that cost, the net income from operations increased 26.3 percent.

Some of those eliminated positions in computer-oriented areas were brought home, and the company now expects to hire project managers in Europe as well as in this region.

The Audubon building has ping-pong and foosball tables, which seem essential for any tech company.

"I'm partial to foosball," Benton joked.

But he is serious about why BioClinica keeps its help desk in-house and staffed 24/7, albeit with a 200-language translation service with another company 30 seconds away by phone. While clinical sites almost always have Internet connections for receiving and transmitting data, sometimes, a voice is more effective at helping humans work through software issues.

"We have a lot of experienced people," Benton said, "and, in one sense, the folks on the help desk are talking to our real customers."

BioClinica to Present at the UBS 22nd Annual Global Healthcare Services Conference

Thu, 26 Jan 2012 09:41:10 -0500

January 26, 2012. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, announced that Mark L. Weinstein, President and Chief Executive Officer will be presenting at the UBS 22nd Annual Global Healthcare Services Conference in New York City on Tuesday, February 7, 2012 at 4:00 p.m. EST.

	Download a printable version of this press release.
	Adobe Reader Required

Mr. Weinstein will be discussing an overview of BioClinica, its business strategy and financial performance.

The Company will provide a live audio broadcast of the presentation. To access this presentation, listeners should go to the Investor Relations section of the Company's website, and access the following link, approximately 15 minutes prior to the event to register and download any necessary software:

www.bioclinica.com/investor-events

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, Microsoft Office-Smart clinical trial management, and clinical supply chain forecasting and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Harrison Clinical Research Selects BioClinica OnPoint CTMS

Tue, 17 Jan 2012 09:48:21 -0500

– Leading European CRO Chooses 'Flexible and Affordable' Clinical Trial Management (CTMS) Technology –

January 17, 2012. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, announced today a new agreement with Harrison Clinical Research (HCR), an international full-service contract research organization. After notification that support for its previous CTMS solution would be discontinued, Harrison selected BioClinica OnPoint CTMS to replace that system. HCR decided that OnPoint is the best-in-class solution to provide services to its world-wide client base. Harrison currently supports approximately 80 clinical trials for its clients annually.

	Download a printable version of this press release.
	Adobe Reader Required

"After an extensive product search, we were impressed with BioClinica's technology and the operational efficiencies that it affords," said Monika Huber, Group Compliance Manager and Project Director of Harrison Clinical Research. "A robust CTMS system is critical for us to support trial management and optimal communication with our clients. Both our IT and clinical teams liked BioClinica's team and the technology, and in particular, how flexible and affordable it was compared to other solutions. BioClinica's product roadmap for OnPoint convinced us that it is the right partner for the long haul."

Harrison's in-depth selection process included a pilot project that offered users hands-on validation of OnPoint's capabilities and ease-of-use. "Harrison was already a Microsoft® SharePoint® customer," said Ms. Huber, "and when we saw the offline capabilities – through OnPoint to Outlook and Microsoft Office – we were even more impressed." BioClinica OnPoint leverages native connectivity through SharePoint to extend workflow management to Microsoft Office applications which allow end users to do much of their work using their familiar desktop applications.

"BioClinica is delighted to be chosen by Harrison Clinical Research for its world-wide clinical trial management needs after such a thorough selection process," said Peter Benton, President of eClinical Solutions for BioClinica. "Since launching the latest release of the product eight months ago, we have seen tremendous interest in OnPoint's ability to support global research combined with the flexibility sponsors need to create more efficient eClinical environments."

BioClinica OnPoint CTMS capabilities include: clinical site, personnel, patient and clinical supplies administration; scheduling, tracking and performance monitoring; site payments, study document management; and more. OnPoint CTMS is supported by Microsoft SharePoint and BioClinica technologies to provide superior team collaboration, connectivity and efficiency for multi-site implementations.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About the Harrison Clinical Research Group
Harrison Clinical Research (HCR) is an international contract research organization offering full service clinical research capabilities to the pharmaceutical industry. With Phase I (clinical pharmacology unit in Munich, Germany) to Phase IV capabilities, HCR focuses on providing the services our clients require for the successful clinical development and registration of new pharmaceutical, biological and nutraceuticals products as well as medical devices by delivering the highest quality data, achieving promised enrollment and meeting project timelines.

Bioclinica, Inc. to Sponsor and Lead Discussion at Key Clinical Trial Industry Events

Tue, 10 Jan 2012 11:58:38 -0500

– Experts Will Present Perspectives on Regulatory Guidances and Driving Clinical Trial Efficiency –

NEWTOWN, PA, January 10, 2012 – BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in and speak at upcoming industry conferences during the first quarter of 2012. BioClinica experts will discuss industry trends and also demonstrate its advanced suite of clinical trial technologies and service solutions.

	Download a printable version of this press release.
	Adobe Reader Required

The events include:

Imaging in Clinical Trials – An Overview of the New FDA Guidance and Its Impact
January 12, 2012 11:00 a.m. (EST)
*WEBINAR*

The FDA has recently issued a draft Guidance for Industry on Standards for Clinical Trial Imaging Endpoints. This guidance describes procedures recommended for interpreting and collecting medical images in clinical trials. This webinar will provide a brief historical perspective of the regulatory view of medical imaging in clinical tirals that led to this guidance followed by a comprehensive overview of the document as it currently stands. The potential impact of this guidance to sponsors, sites and core labs will be discussed.

To register please visit: http://www.bioclinica.com/webinar-imaging-in-clinical-trials-new-fda-guidance/

The New FDA Draft Guidance – What It Means to Me as a Site, a CRA and a Data Manager
Part 1: January 19, 2012 11:00 a.m. (EST)
Part 2: January 26, 2012 11:00 a.m. (EST)
*WEBINAR*

The FDA has recently issued draft guidances for Industry on Standard for Clinical eSource and Risk-Based Approaches to monitoring which have a broad impact on almost all facets of the clinical trial management. This webinar series will discuss the impact of recent FDA guidances on industry and approaches to prepare to implementnew strategies.

To register please visit: http://www.bioclinica.com/webinar-the-new-fda-draft-guidances-what-it-means-to-me/

Life Sciences Innovation Forum
January 26 – 27, 2012
Marriott Forrestal Village Conference Center
Princeton, NJ

BioClinica will lead a panel discussion “Implementing a New Approach to Clinical Trial Management, the Clinical Trials Framework.” Topics will include:

How traditional systems have failed to meet their promise
Driving new efficiencies and processes to improve drug development throughout the clinical phase
Enhanced collaboration – approaches to access, share and analyze clinical data more efficiently

Panel members:

Dan Delaney, Clinical Project Manager, CR BARD
Robert Leonard, Chief Information Officer, Harvard Clinical Research Institute
Brandon Cheal, Commodity Manager, R&D, Johnson & Johnson
Peter Benton, President, eClinical Solutions, BioClinica, Inc.
Miguel Amador, Clinical Project Manager, Johnson & Johnson Vision Care, Inc.

Outsourcing in Clinical Trials West Coast
February 15 - 16, 2012
San Francisco Airport Marriott Waterfront
San Francisco, CA
Outsourcing in Clinical Trials joins major pharma and biotech manufacturers to debate potential solutions to complex challenges. Due to a difficult economic environment, it is important to make the best use of all available resources. As a leading provider of outsourced clinical trial services, BioClinica will demonstrate its efficient and cost-effective suite of clinical trial solutions.

Partnerships in Clinical Trials 2012
March 5 - 7, 2012
The Marriot World Center
Orlando, FL
Booth # 215
BioClinica will demonstrate its expanded suite of integrated clinical trial services that maximize efficiency and manageability of the clinical trial process at this clinical operations and outsourcing event. This event attracts nearly 2,000 of the world's most strategic clinical trial executives to one location.

24th Annual Euro DIA Meeting
March 26 –28, 2012
Bella Center
Copenhagen, Denmark
Booth # 138
This conference hosts more than 3,000 professionals from over 50 countries, including professionals from the biopharmaceutical industry, contract service organizations, academic research centers, regulatory agencies and health ministries, including representatives from the EMEA, FDA and regulatory agencies throughout Europe will be in attendance. As BioClinica's global delivery spans 15,000 sites in 88 countries, this conference will showcase its integrated suite of clinical trial services to influential members of the global biopharmaceutical industry.

CBI's 5th Annual Forum on Clinical Trials Management Systems (CTMS)
March 22 - 23, 2012
Doubletree Hotel Philadelphia Center City
Philadelphia, PA
CBI’s 5th Annual Forum on Clinical Trial Management Systems is an event for clinical business and IT professionals to learn from the challenges and successes of their industry counterparts. This meeting addresses the adoption and integration of CTMS systems across the organization as well as working with drug development partners. BioClinica’s Jeremiah Rehm, eClinical Solutions Specialist, will co-present Workshop B on March 22nd from 7:30 a.m. -12:15 p.m. on “Building the Pathways Between Sponsors, CROs and Site to Share CTMS Data.” During this workshop attendees will learn the best practices in developing pathways between sponsors and CROs, what common pitfalls to avoid and lastly, how to determine what information should be shared.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica to Host Fourth Quarter and Year-End 2011 Financial Results

Fri, 06 Jan 2012 09:27:57 -0500

– Conference Call to be Held at 11:00 a.m. EST –

January 6, 2012. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, will release its financial results for the fourth quarter and year ended December 31, on Thursday, February 9, 2012.

	Download a printable version of this press release.
	Adobe Reader Required

Management of BioClinica, Inc. will host a conference call on the same day at 11:00 a.m. EST. Those who wish to participate in the conference call may telephone 877-869-3847 from the U.S.; international callers may telephone 201-689-8261, approximately 15 minutes before the call. There will be a simultaneous webcast on www.bioclinica.com. A digital replay will be available by telephone approximately two hours after the call’s completion for two weeks, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, Acct # 360; Replay ID # 386423. The replay will also be on the website under “Investor Relations” at www.bioclinica.com for two weeks.

Onconova Selects BioClinica Express Electronic Data Capture Solution

Wed, 30 Nov 2011 10:29:36 -0500

– Oncology Pioneer Leverages BioClinica EDC Technology to Accelerate Development of New Therapies –

November 30, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management and EDC solutions, today announced that Onconova Therapeutics®, Inc. has extended agreements using BioClinica Express electronic data capture (EDC) solution and data management services to support their clinical trials world-wide. Onconova has a number of clinical-stage products and a growing number of pre-clinical candidates. These development stage compounds are novel small molecules for the treatment of a broad range of hematologic malignancies and solid tumors.

	Download a printable version of this press release.
	Adobe Reader Required

"We collaborate with a number of Clinical Research Organizations," said Dennis C. Earle, Vice President of Clinical Operations at Onconova, "so using BioClinica Express EDC solution for our trials has helped us to standardize processes. BioClinica has been flexible and responsive, implementing a collaborative, real-time UAT (user acceptance testing) process to help Onconova meet study launch timelines. BioClinica's Forms and Study Design Team, in conjunction with the Data Management team, have worked together to ensure optimal use of the technology while re-using established eCRFs (electronic case report forms) in order to support rapid study builds."

Onconova has benefited from a number of eCRFs and tools developed by BioClinica specifically to support oncology clinical trials. BioClinica Express EDC solution offers standard RECIST (Response Evaluation Criteria In Solid Tumors) eCRFs that automatically calculate overall tumor response based on the data entered. A dynamic lesion form uses derived data to help sites consistently track lesions from visit to visit. BioClinica's preconfigured library of oncology forms also includes functionality that guides sites through adding adverse events in a way that eliminates the coding step required when entering verbatim terms, and allows the site to fully understand the National Cancer Institute CTCAE (Common Terminology Criteria for Adverse Events) grades available for each particular event. BioClinica also worked with Onconova to develop a custom study drug re-supply algorithm to support its unique study design, implemented a daily lab import feed to minimize data entry and a local lab range import to streamline reconciliation.

"The approach being employed by Onconova represents some of the most innovative cancer research in the country, and we are proud to support those efforts," said Peter Benton, President of eClinical Solutions for BioClinica. "The selection of BioClinica by Onconova reaffirms our cutting-edge and user-friendly EDC technology. It also demonstrates BioClinica's ability to deliver effective clinical research solutions for sponsors and Clinical Research Organizations of any size, and for all clinical trial phases and therapeutic categories."

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About Onconova Therapeutics®, Inc.
Onconova, based in Newtown, PA and Pennington, NJ, and founded in 1998, discovers and develops novel small molecule therapeutics targeting signal transduction, cell-cycle, and DNA repair pathways. Onconova has a novel discovery platform focusing on non-ATP competitive kinase inhibitors. These products, technologies, and candidates are derived internally from a proprietary library of new chemical entities. In addition to rigosertib and other anti-cancer drug candidates, Onconova is also developing Ex-RAD® (ON 01210.Na) as a novel radiation protectant (oral and injection) against radiation injury of tissue and whole body. For additional information, please visit http://www.onconova.com.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica Announces Third Quarter 2011 Financial Results

Wed, 09 Nov 2011 15:52:17 -0500

– Conference Call Today at 11:00 A.M. EDT –

November 9, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management and technology solutions, today announced its financial results for the third quarter and nine months ended September 30, 2011.

	Download a printable version of this press release.
	Adobe Reader Required

Financial highlights for the three months ended September 30, 2011 include:

Service revenues increased 4.1% to $16.6 million as compared with $16.0 million for the same period in 2010.
GAAP operating income was $479,000 (which included a restructuring charge of $1.0 million) as compared with $1.3 million for the same period in 2010.
GAAP net income was $358,000, or $0.02 per fully diluted share (which included a restructuring charge of $676,000, or $0.04 per share) as compared with $808,000, or $0.05 per fully diluted share, for the same period in 2010.
Non-GAAP operating income increased 8.2% to $2.0 million as compared with $1.9 million for the same period in 2010.
Non-GAAP net income increased to $1.4 million as compared with $1.2 million for the same period in 2010; on a fully diluted basis, non-GAAP earnings per share increased to $0.08 per fully diluted share as compared with $0.07 per fully diluted share reported for the same period in 2010.
Backlog increased 8.7% to $115.6 million as of September 30, 2011 as compared with $106.3 million as of September 30, 2010.

Financial highlights for the nine months ended September 30, 2011 include:

Service revenues increased 7.4% to $49.7 million as compared with $46.2 million for the same period in 2010.
GAAP operating income was $2.5 million as compared with $3.1 million for the same period in 2010.
GAAP net income was $1.6 million, or $0.10 per fully diluted share, as compared with $1.9 million, or $0.12 per fully diluted share, for the same period in 2010.
Non-GAAP operating income increased 17.5% to $5.9 million as compared with $5.0 million for the same period in 2010.
Non-GAAP net income increased to $3.8 million as compared with $3.1 million for the same period in 2010; on a fully diluted basis, non-GAAP earnings per share increased to $0.23 per fully diluted share as compared with $0.20 per fully diluted share reported for the same period in 2010.

"We continue to build our reputation in the industry for providing superior integrated clinical research technology solutions to our clients. With a full range of hosted and SaaS solutions, we support a growing number of clinical trials across the world," said Mark L. Weinstein, President and CEO of BioClinica. "Our third quarter results reflect the progress we have made as our clients seek improved speed and efficiency to implement and execute their clinical trials. These improvements reflect the momentum that is building across all areas of our business, including increased interest in our core medical imaging services, Express EDC, OnPoint CTMS, Optimizer and Trident IVR/IWR. In addition to a growing revenue base, our continued development of our BioPACS™ imaging management system is resulting in efficiency gains that have contributed to improved year-over-year non-GAAP operating income."

"Further, as clinical trial sponsors continue to reduce the number of vendors they use by selecting providers who can fulfill more of their clinical trial software and imaging needs, BioClinica's best-of-breed, interoperable platforms are gaining more traction across the industry. In addition to a growing base of pharmaceutical and medical device clients, we are also experiencing increased interest from leading CROs to serve as their preferred providers for their global clinical trials," Mr. Weinstein continued.

Two weeks ago BioClinica hosted its first annual eClinical users conference at the Microsoft Technology Center in Malvern, Pennsylvania. The two-day meeting was attended by over 80 current and prospective clients that ranged from the largest pharmaceutical and medical device companies to small biotech companies. In commenting on the successful conference, Mr. Weinstein said, "Some of the most rewarding results of this conference were hearing our current clients talk about how satisfied they are with the solutions we provide them, and having them share their ideas on how we can continue to further advance our products and services."

"With increased sales of our products and a strong backlog, we are on track to meet our previously issued guidance. We are reiterating our expectations for full-year 2011 service revenues to be in the range of $66 to $70 million, our full-year GAAP EPS, including a restructuring charge of $0.07 per share, to be in the range of $0.16 to $0.21 per diluted share, and our full-year non-GAAP EPS to be in the range of $0.30 to $0.35 per diluted share," he concluded.

During the third quarter, BioClinica purchased 51,700 shares of its stock at an average price of $4.81 per share, as part of its stock repurchase program. For the nine months ended September 30, 2011, BioClinica purchased 156,713 shares of its stock at an average price of $5.04 per share. At September 30, 2011, there was $1.2 million of funds remaining that may yet be used to repurchase shares under the plan that originally authorized purchases up to $2 million.

Conference Call Information
Management of BioClinica, Inc. will host a conference call today at 11:00 a.m. EST. Those who wish to participate in the conference call may telephone 877-869-3847 from the U.S.; international callers may telephone 201-689-8261, approximately 15 minutes before the call. There will be a simultaneous webcast on www.bioclinica.com. A digital replay will be available by telephone approximately two hours after the call’s completion for two weeks, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, Acct # 360; Replay ID # 380957. The replay will also be on the website under "Investor Relations" at www.bioclinica.com for two weeks.

Non-GAAP Financial Information
BioClinica is providing information on 2011 and 2010 non-GAAP income from operations, non-GAAP net income and non-GAAP diluted earnings per share that exclude certain items, as well as the related income tax effects, because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. The non-GAAP information excludes, certain of which are recurring in nature, the impact of stock-based compensation, amortization of intangible assets related to acquisitions, restructuring charges and merger and acquisition costs. We believe the non-GAAP information provides supplemental information useful to investors in comparing our results of operations on a consistent basis from period to period. Management uses these non-GAAP measures in assessing our core operating performance and evaluating our ongoing business operations. These measures are not in accordance with, or an alternative for, generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. Therefore, the information may not necessarily be comparable to that of other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Investors are encouraged to review the reconciliations of these non-GAAP financial measures to the comparable GAAP results, which are included below in this press release.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

– FINANCIAL TABLES TO FOLLOW –

BIOCLINICA, INC. AND SUBSIDIARIES Consolidated Statements of Income (In thousands, except per share data) (unaudited)
	For the Three Months Ended		For the Nine Months Ended
	09/30/11	09/30/10	09/30/11	09/30/10

Service revenues	16,623	15,969	49,658	46,248
Reimbursement revenues	4,847	2,352	11,887	9,413
Total revenues	$ 21,470	$ 18,321	$ 61,545	$ 55,661

Costs and expenses:
Cost of service revenues	10,434	10,212	31,432	29,109
Cost of reimbursement revenues	4,847	2,352	11,887	9,413
Sales & marketing expenses	2,081	2,090	6,324	6,865
General & admin. expenses	2,434	2,069	7,027	6,057
Amortization of intangible assets related to acquisitions	155	194	467	473
Mergers & acquisition related costs	-	119	162	635
Restructuring charges	1,040	-	1,719	-
Total cost and expenses	20,991	17,036	59,018	52,552
Operating income	479	1,285	2,527	3,120
Interest income (expense) – net	___(12)	____10	___(26)	____11
Income before income tax	467	1,295	2,501	3,120
Income tax provision	109	487	__ 868	__1,198
Net income	358	808	1,633	1,922


Basic earnings per share	$ 0.02	$ 0.05	$__ 0.10	$___0.13

Weighted average number of shares - basic	15,640	15,174	15,645	14,958

Diluted earnings per share	$ 0.02	$ 0.05	$ 0.10	$ 0.12

Weighted average number of shares – diluted	16,383	15,796	16,515	15,730

BIOCLINICA, INC. AND SUBSIDIARIES GAAP to non-GAAP Reconciliation (1) (In thousands, except per share data) (unaudited)
	For the Three Months Ended		For the Nine Months Ended
	09/30/11	09/30/10	09/30/11	09/30/10

GAAP income from continuing operations before interest and taxes	479	1,285	2,527	3,120
Stock-based compensation*	349	271	1,021	791
Amortization of intangible assets related to acquisitions	155	194	467	473
Merger & acquisition related costs	-	119	162	635
Restructuring charges	__1,040	_____-	__1,719	_____-
Non-GAAP operating income	2,023	1,869	5,896	5,019


GAAP net income	358	808	1,633	1,922
Stock-based compensation, net of taxes	227	167	664	487
Amortization of intangible assets related to acquisitions, net of taxes	101	120	304	291
M&A related cost, net of taxes	-	73	105	391
Restructuring charges, net of taxes	676	-	1,117	-
Non-GAAP net income	1,362	1,168	3,823	3,091
GAAP diluted earnings per share	$___0.02	$___0.05	$__0.10	$__0.12

Non-GAAP diluted earnings per share	$ 0.08	$ 0.07	$ 0.23	$ 0.20

*Stock based compensation included in total costs and expenses is as follows:
Cost of service revenues	120	97	351	284
Sales and marketing expenses	11	13	30	37
General and admin. expenses	___218	___161	___640	___470
Total stock-based compensation	___349	___271	__1,021	___791

(1) This table presents a reconciliation of GAAP to non-GAAP income from continuing operations before interest and taxes, income from continuing operations, net of taxes and diluted earnings per share for the three months and years ended December 31, 2009 and 2008. The non-GAAP information excludes the impact of stock-based compensation, amortization of intangible assets related to acquisitions, restructuring charges and merger and acquisition costs.

BIOCLINICA, INC. AND SUBSIDIARIES Consolidated Balance Sheets (In thousands) (unaudited)
ASSETS
	September 30, 2011	December 31, 2010
Current assets:
Cash and cash equivalents	$ 12,292	$ 10,443
Accounts receivable, net	13,482	11,866
Prepaid expenses and other current assets	2,594	2,501
Deferred income taxes	___4,098	___3,625
Total current assets	32,466	28,435
Property & equipment, net	15,459	14,029
Intangibles, net	1,963	2,430
Goodwill	34,302	34,302
Deferred income taxes	87	128
Other assets	____748	___705
Total assets	$ 85,025	$ 80,029
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$ 2,168	$ 1,983
Accrued expenses and other current liabilities	4,185	4,283
Deferred revenue	13,377	13,395
Current maturities of capital lease obligations	342	168
Long-term liability for acquisition earn-out	2,000	-
Total current liabilities	22,072	19,829
Long-term of capital lease Obligations	1,296	710
Long-term liability for acquisition earn-out	-	1,886
Deferred income taxes	3,107	1,845
Other liability	___1,621	___880
Total liabilities	_ 28,096	25,150
Stockholders’ equity:
Common stock	4	4
Treasury stock	(800)	(16)
Additional paid-in capital	49,231	48,074
Retained earnings	8,425	6,792
Accumulated other comprehensive income	_____69	_____25
Total stockholders’ equity	56,929	54,879
Total liabilities & stockholders’ equity	$ 85,025	$ 80,029

BIOCLINICA, INC. AND SUBSIDIARIES Consolidated Statements of Cash Flows (In thousands) (unaudited)
	For the Nine Months Ended
	9/30/11	9/30/10
Cash flows from operating activities:
Net income	1,633	1,922
Adjustments to reconcile net income to net cash provided by Operating activities:
Depreciation and amortization	3,310	2,501
Provision for deferred income taxes	829	47
Bad debt (recovery) expense	(15)	(9)
Stock based compensation expense	1,019	791
Accretion of acquisition earn-out	114	245
Changes in operating assets and liabilities:
Increase (decrease) in accounts receivable	(1,603)	278
Increase in prepaid expenses and other current assets	(89)	(652)
(Increase) decrease in other assets	(42)	17
Increase (decrease) in accounts payable	113	(199)
Decrease in accrued expenses and other current liabilities	(89)	(1,136)
Decrease in deferred revenue	(19)	(1,127)
Increase in other liabilities	______742	_____368
Net cash provided by operating activities	$ 5,903	$ 3,073

Cash flows from investing activities:
Purchases of property and equipment	(1,352)	(2,296)
Capitalized software development costs	___(2,843)	___(3,783)
Net cash used in investing activities	$ (4,195)	$ (6,079)

Cash flows from financing activities:
Proceeds from sale/leaseback	918	195
Payments under equipment lease obligations	(157)	-
Purchase of treasury stock	(784)	-
Excess tax benefit related to stock options	-	35
Proceeds from exercise of stock options	138	21
Net cash provided by financing activities	$ 115	$ 251

Effect of exchange rate changes on cash	26	1

Net increase (decrease) in cash and cash equivalents	1,849	(2,754)
Cash and cash equivalents at beginning of period	10,443	14,570
Cash and cash equivalents at end of period	$ 12,295	$ 11,816

BioClinica Celebrates 10th Consecutive Year as a Deloitte Fast 50 Company

Mon, 24 Oct 2011 14:26:52 -0400

– Clinical Trials Solution Provider Attributes 87 Percent, Four-Year Total Revenue Increase to Solid Growth Strategy and Continued Employee Commitment –

October 24, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced it ranked 30 on Deloitte's 2011 Greater Philadelphia Fast 50 ranking of the 50 fastest growing technology, media, telecommunications, life sciences and clean technology companies in the Greater Philadelphia region. This is the tenth year in a row that BioClinica has been recognized as one of the region's top companies.

	Download a printable version of this press release.
	Adobe Reader Required

BioClinica's chief executive officer, Mark Weinstein, credits a solid growth strategy and unparalleled customer-focused technologies and services with the company's 87 percent, four-year total revenue growth.

"We are proud to be recognized by Deloitte as a leading company in the Philadelphia area for the tenth year in a row," said Mr. Weinstein. "BioClinica's growth strategy has brought great success to both us and our clients. Our entire team works incredibly hard every day to provide the industry's best service to the various sponsors and CROs we support. Our customer partnerships are why BioClinica is an industry leader. This recognition is a testament to our employees' continued commitment to excellence."

"BioClinica, like all 2011 Greater Philadelphia Fast 50 companies, has excelled in fostering innovation and channeling it into spectacular growth -- against the backdrop of one of the most challenging economies in history," said Tara L. Weiner, managing partner, Greater Philadelphia region, Deloitte LLP. "Deloitte recognizes BioClinica for its remarkable accomplishment."

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About Deloitte's 2011 Greater Philadelphia Fast 50
The 2011 Greater Philadelphia Fast 50, which was conducted by Deloitte & Touche LLP, a subsidiary of Deloitte LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private - in the Greater Philadelphia region. 2011 Greater Philadelphia Fast 50 award winners are selected based on percentage fiscal year revenue growth from 2006 to 2010. In order to be eligible for 2011 Greater Philadelphia Fast 50 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD, and current-year operating revenues of at least $5 million USD. Additionally, companies must be in business for a minimum of five years, and be headquartered within the Greater Philadelphia region.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Microsoft Technology Center to Host BioClinica User Conference

Fri, 21 Oct 2011 11:02:02 -0400

– Enterprise-Wide Cost Efficiencies and Trial Standardization Results Ahead of Targets –

October 21, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of eClinical solutions, announced that Microsoft will host the upcoming 2011 BioClinica User Conference. This meeting will offer participants insightful user presentations and case studies, interactive breakout group sessions, and updates on BioClinica's eClinical product roadmap and corporate vision. Activities also include the opportunity to network with colleagues with similar interests and experiences.

	Download a printable version of this press release.
	Adobe Reader Required

"We appreciate the opportunity for Microsoft to host this important event for BioClinica's clients," said Steve Aylward, General Manager, Microsoft US Commercial Health & Life Sciences. "Microsoft and BioClinica are working together to deliver superior technology solutions that support clinical research. Bringing users and partners together at this event will improve understanding of BioClinica's vision for their products while encouraging collaboration and sharing best practices that will lead to more efficient clinical trials."

This year's meeting will be held in Malvern, PA and will be comprised of users of BioClinica's complete suite of eClinical applications, including: Express EDC, Trident IWR, OnPoint CTMS and Optimizer supplies forecasting.

When: October 25 – October 26, 2011
Where: Microsoft Technology Center, 45 Liberty Boulevard, Malvern, PA 19355

"There has never been a better time to be a BioClinica partner," said Peter Benton, President of eClinical Solutions for BioClinica. "BioClinica's combination of transformative technology and service innovation provides clients with a huge opportunity to successfully address many of the challenges they face in the execution of global clinical studies. We are grateful to Microsoft for their ongoing alliance and support as well as for hosting our 2011 BioClinica User Conference."

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica to Host Third Quarter 2011 Financial Results

Mon, 17 Oct 2011 10:26:09 -0400

– Conference Call Today at 11:00 A.M. EDT –

October 17, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a leading global provider of clinical trial management services, will release its financial results for the third quarter ended September 30, 2011, on Wednesday, November 9, 2011.

	Download a printable version of this press release.
	Adobe Reader Required

Management of BioClinica, Inc. will host a conference call on the same day at 11:00 a.m. EST. Those who wish to participate in the conference call may telephone 877-869-3847 from the U.S.; international callers may telephone 201-689-8261, approximately 15 minutes before the call. There will be a simultaneous webcast on our company website. A digital replay will be available by telephone approximately two hours after the call's completion for two weeks, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, Acct # 360; Replay ID # 380957. The replay will also be on the website under "Investor Relations" for two weeks.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica Appoints Senior Medical Director - Dr. Andrzej Dzik-Jurasz

Mon, 26 Sep 2011 10:22:50 -0400

– New Position Expands Scientific Coverage for MRI Imaging and Oncology –

September 26, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced the appointment of Andrzej (Andy) Dzik-Jurasz, M.D., Ph.D. as Senior Medical Director for Medical Affairs, a newly created position. Dr. Dzik-Jurasz brings more than 15 years of clinical, radiological and pharmaceutical industry experience with major pharmaceutical companies such as Novartis Pharmaceuticals and GlaxoSmithKline.

	Download a printable version of this press release.
	Adobe Reader Required

"Dr. Dzik-Jurasz's appointment to this newly created position will help support BioClinica's growth initiatives within our imaging core lab solutions business," said Mark Weinstein, CEO of BioClinica. "He will be responsible for leading our global oncology strategy, including the development and implementation of new offerings to support our clients' clinical studies. Andy's expertise in MRI imaging also provides additional depth for our imaging clientele."

Dr. Dzik-Jurasz is widely published in radiology with more than 40 publications in clinical and research journals. His academic and pharmaceutical industry experience has focused on imaging in clinical drug development. He has participated in all facets of the clinical trial process from Phase I to IV, with particular expertise in the field of oncology.

Dr. Dzik-Jurasz will report to Colin Miller, Ph.D. FICR CSci, Senior Vice President of Medical Affairs, who added, "Andy is a gifted and disciplined researcher who will make an immediate contribution to BioClinica's culture of excellence and innovation for clinical trial support. His exceptional qualifications as a physician investigator combine an impressive scientific track record with a passion for the use of imaging in drug development. We are extremely pleased to have him join our team."

Dr. Dzik-Jurasz joins BioClinica from Novartis where he held the position of Executive Director, Global Head Oncology Translational Imaging. Prior to that he was Vice President of Clinical Development for Point Therapeutics; Head of Imaging for Epix Pharmaceuticals, and Senior Director in Translational Medicine and Technology at GlaxoSmithKline. Dr. Dzik-Jurasz received his medical degree from Westminster Medical School, London, UK, and his Ph.D. from the Institute of Cancer Research, London, UK. He is a Fellow of the Royal College of Surgeons of England and Fellow of the Royal College of Radiologists.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica Websend Effects Rapid Change in Clinical Trial Image Management

Wed, 21 Sep 2011 10:28:12 -0400

September 21, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, announced that BioClinica WebSend has been included in more than 90% of its 2011 imaging core lab business signings. WebSend benefits clinical trials by speeding access to clinical imaging data while reducing errors and costs by securely sending medical images over the Internet, rather than using courier services.

	Download a printable version of this press release.
	Adobe Reader Required

"The ease of use and resulting high adoption rate by sites have encouraged nearly every one of our top imaging core lab clients to implement this clinical imaging technology," said Mark Weinstein, CEO of BioClinica. "Unlike alternatives, all of the system capabilities are fully integrated with our core lab processes to streamline the collection, processing, archival and analysis of medical image data. The simplicity and speed of WebSend make the business case direct and compelling."

WebSend is the most comprehensive clinical imaging solution available for effectively managing electronic image receipt and de-identification from investigator sites. In addition to image transfer, it also includes online viewing of images, web-based reporting for key stakeholders (including trial sponsors), and "cloud-based" image archiving. WebSend integrates with BioClinica onsite image archival and workflow management tools (BioPACS) and read systems (BioREAD) which house imaging reader response data, protocol-specific eCRFs, and more.

"Compared to the history of many other clinical imaging technologies, WebSend adoption is truly dramatic," said Mr. Weinstein. "WebSend addresses the economic and process improvement pressures that face clinical development with clear and present benefits. It's an easy choice for most sponsors."

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica Announces Major New Release of Express EDC Solution

Mon, 12 Sep 2011 10:50:30 -0400

– Interoperability with Trident IWR and OnPoint CTMS Redefines Suite –

September 12, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, announced the latest release of BioClinica Express EDC. This modern, web-based platform is a comprehensive electronic data capture (EDC) solution that adds speed and quality to every part of the clinical trial process. Enhanced to utilize the latest web technologies, Express EDC makes it easier to monitor protocol compliance and close studies faster while meeting necessary regulations and guidelines. The newest Express application improves on the usability that sites already consider 'easiest' with flexible, scalable technology that coordinates and organizes the collection and dissemination of clean data.

	Download a printable version of this press release.
	Adobe Reader Required

Express joins BioClinica's other solutions to improve the efficiency and flexibility required for modern clinical trials. Express is fully integrated in real-time with BioClinica's Trident IWR and OnPoint CTMS systems. This enables real time data exchange between Express and OnPoint CTMS to support site payment data or visit status updates. Complementing best-in-class functionality is a web services architecture that communicates in real-time between applications and maximizes data visibility and utility via SharePoint with built-in connectivity to Outlook and other Microsoft Office applications. Express also provides on-demand exports for further analysis in SAS or other analytical tools.

"This release of Express EDC is a major advancement for the BioClinica Suite. Sponsors and CROs can choose any of our world-class solutions as a stand-alone or a starting point - then augment functionality for any study when they need it," said Peter Benton, President of eClinical Solutions for BioClinica. "With the only portfolio of eClinical applications all created within the last five years, BioClinica offers a remarkably different approach with fresh ideas to address the challenges facing clinical organizations globally."

BioClinica Express provides new capabilities for EDC power users that make slicing and dicing incoming data fast and easy and automatically encodes medical terms within the same application. Role-specific dashboards focus attention where it's needed the most and data managers can tag or bookmark data to facilitate workflow, save customized data and query listings as 'private' or 'public' for later use. Study build timelines are minimized using an innovative design environment that reduces programming and maximizes re-usability.

Express delivers CDISC-compliant output at the end of the trial to save sponsors time and maximize exchange or integration with partners. Express can also incorporate external data such as labs, PK data, imaging metadata, and other instrumentation data with the clinical data during the trial. This process eliminates end-of-study reconciliation, provides cleaner data faster, and simplifies the submission process.

See BioClinica Express EDC at the 2011 SCDM (Society for Clinical Data Management) Annual Conference in Baltimore at booth #401.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Optinose Selects BioClinica Trident IWR, Optimizer and Imaging Core Lab Solutions

Thu, 08 Sep 2011 10:05:42 -0400

– Drug Delivery Company Selects BioClinica for Roster of Clinical Trials –

September 8, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that OptiNose, Inc. selected BioClinica Trident IWR, Optimizer clinical supplies forecasting, and Imaging Core Lab services for use in a series of clinical trials including several pivotal Phase III studies.

	Download a printable version of this press release.
	Adobe Reader Required

"OptiNose's goal was to employ the best available technology to help us develop the highest quality products in the most efficient manner," said Colette Kosik-Gonzalez, Senior Director, Clinical Development, OptiNose, Inc. "After a thorough competitive assessment of the leading solutions, we selected BioClinica for high-quality medical image management services and cutting-edge IVR technology to provide us with maximum efficiencies throughout our programs."

OptiNose's analysis found BioClinica Optimizer and Trident IWR products to be extremely user-friendly, with the added benefit of significantly reducing study build time. OptiNose also determined that the combination of Trident and Optimizer would ease trial management and help control costs by continually assessing clinical supply requirements throughout the trial.

"Award-winning technology and a talented services group are some of the reasons why innovative companies like OptiNose choose BioClinica's advanced imaging and IWR solutions," said Mark Weinstein, CEO of BioClinica. "BioClinica's approach to supporting clinical trials is based on the understanding that trial managers want better alternatives and fewer complications to support their clinical projects. With increasing frequency, clients realize the benefits of BioClinica's services suite and select multiple products to meet their needs. OptiNose is one such example of this trend, and we are pleased to help them manage their clinical trials with greater efficiency and accuracy."

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About OptiNose Inc.
OptiNose is a drug delivery company with breakthrough bi-directional nasal technology set to transform the static nasal drug delivery market. Founded in 2000, OptiNose's devices are designed to deliver intranasal drugs to target regions of the nasal cavity, including the sinuses and the olfactory region while preventing lung deposition. The company offers both single and multi-use intranasal delivery devices for liquid and powder formulations. The technology has been successfully tested in a number of clinical trials demonstrating both clinical efficacy and safety. Investors in OptiNose include Avista Capital Partners in New York, WFD Ventures LLC located in New York and Entrepreneurs Fund LP based in Jersey, Channel Islands. For more information please visit www.OptiNose.com.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica to Showcase Knowledge and Expertise of Clinical Trial Management

Tue, 06 Sep 2011 12:09:36 -0400

– Company Thought Leaders to Present and Participate at Industry Meetings –

September 6, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, will attend and speak at key industry conferences throughout the third and fourth quarters of 2011. Key BioClinica experts will provide insights into current industry topics and trends, as well as present the company’s expanded suite of technology capabilities and offerings.

	Download a printable version of this press release.
	Adobe Reader Required

Jim Dorsey, Vice President of Marketing for BioClinica said, "Our rapid technology evolution has greatly increased the scope and depth of BioClinica's offerings. Participating in these upcoming events and showcasing our portfolio of new products enables clinical professionals to gain direct knowledge about these developments and better understand how our solutions might apply to their challenges."

These events include:

2011 SCDM Annual Conference
September 11-14, 2011
Baltimore Marriott Waterfront
Baltimore, MD
Booth # 401
The SCDM (Society for Clinical Data Management) Annual Conference is the world's largest education event for clinical data managers and related professionals, attracting approximately 650 attendees from across North America and around the world. BioClinica will be the Diamond Sponsor of this event and will showcase its eClinical Services.

ACRP’s NY Metropolitan Chapter Fall Symposium
September 16, 2011
Yale Club of NY
New York, NY
Jonathan Andrus, Vice President of Data Management and Quality, will speak on “Electronic Data Capture Systems – What is going on today and tomorrow?” on September 16 at 8:30 a.m., and will chair a session on: “Compliance and the Digital Age” in the afternoon. BioClinica will also demonstrate its efficient and cost-effective suite of clinical trial solutions at the Association of American Clinical Research Professionals Chapter Fall Symposium.

Outsourcing in Clinical Trials Northeast
September 28-29, 2011
The Boston Park Plaza Hotel & Towers
Boston, MA
Booth # 24
Outsourcing in Clinical Trials Northeast brings together major pharma and biotech manufacturers to debate potential solutions to complex challenges. As the industry struggles to meet the challenges associated with a difficult economic climate, making the best use of available resources is now more important than ever before. As a leading provider of outsourced clinical trial services, BioClinica will demonstrate its efficient and cost-effective suite of clinical trial solutions and imaging solutions.

3rd CROss Alliance Summit
Quality of Data in Clinical Development
October 6-7, 2011
Grand Hotel Eden
Lugano, Switzerland
The Third CROss Summit will pull together the experience of industry and contract research organizations in the entire spectrum of clinical drug development (from drug production to overall project evaluation) focusing on the application of quality systems with the view to increase the accessibility of such experience and stimulate its widest use. BioClinica's Jonathan Andrus, Vice President of Data Management and Quality, will present on October 7 at 11:15 a.m. in a session titled, "EDC-Compliance and validation considerations – A case for common sense."

DIA 5th Annual Clinical Forum
October 10-11, 2011
Congress Center Basel
Basel, Switzerland
The DIA (Drug Industry Association) 5th Annual Clinical Forum brings together industry-leading thinking and practices across the key disciplines of data management, clinical operations, drug safety and medical communication as they relate to the practical and operational aspects of drug development. Jonathan Andrus, BioClinica’s Vice President of Data Management and Quality, will speak about “The Revolving World of eClinical” on Monday, October 10 and 2:00 p.m. The session will discuss the effects resulting from eClinical systems’ replacement of traditional paper systems for collecting data and will explore some of the areas where the industry still struggles with amazingly persistent relics of paper past.

CDISC North American Interchange
October 12-13, 2011
Renaissance Harborplace Hotel
Baltimore, MD
Jonathan Andrus, Vice President of Data Management and Quality, BioClinica, will chair the interactive session "eSource and Healthcare Link," which will take place at on Thursday, October 13 from 10:30 a.m. to 12:00 p.m. with a panel that includes representatives from the Hamamatsu University School of Medicine, CMIC, Oracle and Florida Hospital MIS. CDISC is the Clinical Data Interchange Standards Consortium, the global, open, multidisciplinary, non-profit organization that has established standards to support the acquisition, exchange, submission and archive of clinical research data and metadata.

Clinical Trial Supply East Coast 2011
October 19-20, 2011
Hilton Philadelphia City Avenue
Philadelphia, PA
Reid Tonik, Director of Clinical Supply Chain Optimization, will present "Trends, Benefits and Practices 2011: Survey Results about Clinical Supply Chain Forecasting" on October 19 at 10:00 a.m. During this presentation he will discuss the highlights of a survey recently conducted by BioClinica and Paragon Solutions to establish industry benchmarks for managing clinical trial supplies. BioClinica will also demonstrate its Optimizer clinical supply simulation solution.

CBI’s Interactive Response Technologies for Clinical Trials
November 14-15, 2011
Embassy Suites Philadelphia Airport
Philadelphia, PA
Ed Tourtellotte, Vice President, Product Innovation, will present “From the Dark Ages to the Present Day – Clinical IVR and IWR” on November 14 at 1:15 p.m. During this presentation he will examine the IVR value case and subsequent wide spread adoption. He will also discuss and identify solutions for key challenges, including scalability and speed. BioClinica will also showcase its Trident interactive web response system.

10th Annual Partnerships in Clinical Trials
November 15-18, 2011
Centre de Congrès, Lyon, France
Booth # 325
The 10th Annual Partnerships in Clinical Trials is Europe's largest and most productive networking opportunity for clinical development outsourcing professionals. This conference brings together the most innovative thinkers in clinical development outsourcing from sponsors, CROs and other service providers. BioClinica will demonstrate its efficient and cost-effective suite of clinical trial solutions and imaging solutions.

Follow BioClinica and interact with conference speakers on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Vistakon Achieves Clinical Trial Efficiency Improvements with BioClinica

Wed, 17 Aug 2011 10:35:48 -0400

– Collaboration on EDC Processes and CDISC Standardization Cuts Costs and Reduces Study Launch Time –

August 17, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial software and imaging solutions, announced that Johnson and Johnson Vision Care (JJVC), is ahead of its schedule to achieve efficiencies from its three-year electronic data capture (EDC) and data management agreement with BioClinica signed in October 2010, having reached its target in less than one year.

	Download a printable version of this press release.
	Adobe Reader Required

Johnson and Johnson Vision Care (JJVC) achieved its goal of running paperless clinic studies by using Express EDC for direct data entry while streamlining the study build process. BioClinica data management services are utilized to assure that all data is cleaned and processed in a timely manner. The reduction in the overall study development time to produce study results allows the business to react faster to make important and informed decisions. Studies are built and deployed faster, and study data are available for analysis soon after the last patient last visit (LPLV).

"Our partnership with BioClinica has helped JJVC significantly improve its clinical trial efficiency in a relatively short period of time. JJVC now receives clean data ready for analysis in a matter of a few weeks after last patient out (LPO), which allows us to make decisions based on clinical data faster," said Brian Schwam, MD, Director of Clinical Affairs and Ocular Sciences, at JJVC.

BioClinica Express is a comprehensive EDC solution to coordinate and organize the collection and dissemination of clean data, adding speed and quality to every part of the clinical trial process. BioClinica Full Service EDC adds end-to-end technology and clinical services to JJVC clinical trial operations, including: data management planning, clinical study set-up for electronic data capture (EDC), adverse event reconciliation, clinical data management, and training for the clinical sites and investigators.

Peter Benton, President of eClinical Solutions at BioClinica said, "The BioClinica team and world-class technology have helped Vistakon to centralize and streamline clinical data management operations through process improvements and consistent delivery while simultaneously implementing a program for full CDISC compliance. We look forward to working with Vistakon to expand these initial advances supporting their important clinical research and operations."

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica Reports Record Quarterly Service Revenues

Wed, 03 Aug 2011 11:40:03 -0400

– Non-GAAP Operating Income Increases 45.6% on an 8.7% Increase in Service Revenues –

– Conference Call Today at 11:00 A.M. EDT –

August 3, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced its financial results for the second quarter and six months ended June 30, 2011.

	Download a printable version of this press release.
	Adobe Reader Required

Financial highlights for the quarter ended June 30, 2011 include:

Service revenues increased 8.7% to a record $16.9 million as compared with $15.5 million for the same period 2010.
GAAP income from operations was $1.5 million, as compared with $657,000 for the same period 2010, an increase of 125%.
GAAP net income was $924,000, or $0.06 per fully diluted share, as compared with $403,000, or $0.03 per fully diluted share, for the same period 2010.
Non-GAAP income from operations increased 45.6% to $2.0 million as compared with $1.4 million for the same period 2010.
Non-GAAP net income increased 48.6% to $1.3 million as compared with $851,000; on a fully diluted basis, Non-GAAP earnings per share increased 60% to $0.08 per share, as compared with $0.05 per fully diluted share reported for the same period 2010.
Backlog was $112.5 million as of June 30, 2011, an 8.0% increase as compared with $104.2 million as of June 30, 2010.

Financial highlights for the six months ended June 30, 2011 include:

Service revenues increased 9.1% to $33.0 million as compared with $30.3 million for the same period 2010.
GAAP income from operations was $2.0 million as compared with $1.8 million for the same period 2010, an increase of 12.3%.
GAAP net income was $1.3 million, or $0.08 per fully diluted share, as compared with $1.1 million, or $0.07 per fully diluted share, for the same period 2010.
Non-GAAP income from operations increased 23.4% to $3.9 million as compared with $3.1 million for the same period 2010.
Non-GAAP net income increased 26.3% to $2.4 million compared with $1.9 million in the prior year's period, and was $0.15 per fully diluted share, a 25% increase compared with $0.12 per fully diluted share reported for the same period 2010.
During the second quarter, we repurchased 67,400 shares of BioClinica stock at an average price of $5.19 per share, as part of our stock repurchase program. For the first half of 2011, we purchased 105,013 shares of BioClinica stock at an average price of $5.12 per share. At June 30, 2011, there was $1.4 million of funds remaining that may yet be used to repurchase shares under the plan that originally authorized purchases up to $2 million.

"By providing best-in-class combined technology and service solutions and a clear line of site to a unified clinical research solution, we are getting a tremendous reception from the entire continuum of pharma and medical device companies. The industry is rapidly accepting that a new development paradigm is needed and that the new paradigm requires new solutions, i.e. BioClinica. Our second quarter financial results show the strength of our historical core medical imaging services combined with the ever-increasing acceptance of our new products and services. For the quarter we showed growth across the board, including: service revenue, gross margin on service revenue, operating income, net income and earnings per share, and we ended the quarter with a strong backlog of $112.5 million," said Mark L. Weinstein, President and CEO of BioClinica.

Mr. Weinstein added, "We continue to get tremendous traction on our Trident IVR/IWR product which we released in the fourth quarter of last year. Since its initial launch we have had 11 new clients involving 24 studies commit to the Trident platform for their IVR/IWR needs. Everyone that is introduced to Trident is very pleased with its unparalleled efficiency and accuracy."

"Similar to Trident, we are also beginning to see traction for our OnPoint CTMS, Clinical Trial Management System (‘CTMS') solution," he continued. "Initially oriented towards small- to medium- pharma companies, we are now seeing tremendous interest from major global pharmaceutical companies and medical device companies as well. OnPoint's tight integration with Microsoft® SharePoint enables users to interact with our CTMS solution via Microsoft Office applications (Outlook, Excel, Word, etc.), speeding user adoption and compliance. BioClinica's growth is not only attributed to our technologies that meet and exceed client demands, it is also the result of our agile and innovative staff, including our expert development organization that creates and supports these various technologies."

Mr. Weinstein concluded, "We intend to continue this momentum by broadening our client base and increasing the adoption of our products and services. With our strong backlog, and our continued strengthening of our suite of products and services, we remain on track to achieve our previously issued guidance. We are reiterating our expectations for full-year 2011 service revenues to be in the range of $66 to $70 million, our full-year GAAP EPS, including a restructuring charge of $0.06 per share, to be in the range of $0.16 to $0.21 per diluted share, and our full-year non-GAAP EPS to be in the range of $0.30 to $0.35 per diluted share."

Conference Call Information
Management of BioClinica, Inc. will host a conference call today at 11:00 a.m. EDT. Those who wish to participate in the conference call may telephone 877-869-3847 from the U.S.; international callers may telephone 201-689-8261, approximately 15 minutes before the call. There will be a simultaneous webcast on www.bioclinica.com. A digital replay will be available by telephone approximately two hours after the call's completion for two weeks, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, Acct. # 360; Replay ID # 375931. The replay will also be on the website under "Investor Relations" at www.bioclinica.com for two weeks.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

– FINANCIAL TABLES TO FOLLOW –

BIOCLINICA, INC. AND SUBSIDIARIES Consolidated Statements of Income (In thousands, except per share data) (unaudited)
	For the Three Months Ended		For the Six Months Ended
	6/30/11	6/30/10	6/30/11	6/30/10

Service revenues	16,891	15,533	33,035	30,279
Reimbursement revenues	3,519	3,703	7,040	7,061
Total revenues	$ 20,410	$ 19,236	$ 40,075	$ 37,340

Costs and expenses:
Cost of service revenues	10,441	9,946	20,998	18,897
Cost of reimbursement revenues	3,519	3,703	7,040	7,061
Sales & marketing expenses	2,383	2,565	4,243	4,775
General & admin. expenses	2,371	1,916	4,593	3,988
Amortization of intangible assets related to acquisitions	156	138	312	279
Mergers & acquisition related costs	59	311	162	516
Restructuring charges	_____-	______-	____679	_____-
Total cost and expenses	18,929	18,579	38,027	35,516
Income from continuing operations before interest and taxes	1,481	657	2,048	1,824
Interest income (expense) – net	____(7)	____(2)	___(14)	____1
Income before income tax	1,474	655	2,034	1,825
Income tax provision	_ 550	252	__759	___711
Net income (loss)	924	403	1,275	1,114


Basic earnings per share	$ 0.06	$ 0.03	$ 0.08	$ 0.08

Weighted average number of shares - basic	15,647	15,115	15,649	14,852


Diluted earnings per share	$ 0.06	$ 0.03	$ 0.08	$ 0.07

Weighted average number of shares – diluted	16,491	16,065	16,566	15,861

BIOCLINICA, INC. AND SUBSIDIARIES GAAP to non-GAAP Reconciliation (1) (In thousands, except per share data) (unaudited)
	For the Three Months Ended		For the Six Months Ended
	6/30/11	6/30/10	6/30/11	6/30/10

GAAP income from continuing operations before interest and taxes	1,481	657	2,048	1,824
Stock-based compensation*	329	285	672	520
Amortization of intangible assets related to acquisitions	156	138	312	279
Merger & acquisition related costs	59	311	162	516
Restructuring charges	______-	______-	____679	______-
Non-GAAP income from operations	2,025	1,391	3,873	3,139


GAAP income from continuing operations, net of taxes	924	403	1,275	1,114
Stock-based compensation, net of taxes	206	174	421	317
Amortization of intangible assets related to acquisitions, net of taxes	98	84	196	170
M&A related cost, net of taxes	37	190	102	315
Restructuring charges, net of taxes	______-	______-	____426	______-
Non-GAAP income from continuing operations, net of taxes	1,265	_ 851	2,420	1,916

GAAP diluted earnings per share	$ 0.06	$ 0.03	$ 0.08	$ 0.07

Non-GAAP diluted earnings per share	$ 0.08	$ 0.05	$ 0.15	$ 0.12

*Stock based compensation included in total costs and expenses is as follows:
Cost of service revenues	107	99	230	189
Sales and marketing expenses	8	13	20	26
General and admin. expenses	_____214	_____173	____422	_____305
Total stock-based compensation	_____329	_____285	____672	_____520

(1) This table presents a reconciliation of GAAP to non-GAAP income from operations, net income and diluted earnings per share for the three months and six months ended June 30, 2011 and 2010. The non-GAAP information excludes the impact of stock-based compensation, amortization of intangible assets related to acquisitions, restructuring charges and merger and acquisition costs. (2) The effective tax rate used for fiscal 2011 is 37.3%.

BIOCLINICA, INC. AND SUBSIDIARIES Consolidated Balance Sheets (In thousands) (unaudited) ASSETS
	June 30, 2011	December 31, 2010
Current assets:
Cash and cash equivalents	$ 11,519	$ 10,443
Accounts receivable, net	14,659	11,866
Prepaid expenses and other current assets	2,095	2,501
Deferred income taxes	____3,950	____3,625
Total current assets	32,223	28,435
Property & equipment, net	15,131	14,029
Intangibles, net	2,119	2,430
Goodwill	34,302	34,302
Deferred income taxes	94	128
Other assets	____707	____705
Total assets	$ 84,576	$ 80,029
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$ 4,345	$ 1,983
Accrued expenses and other current liabilities	3,125	4,283
Deferred revenue	13,529	13,395
Current maturities of capital lease obligations	268	168
Long-term liability for acquisition earn-out	___2,000	______-
Total current liabilities	23,267	19,829
Long-term of capital lease Obligations	1,034	710
Long-term liability for acquisition earn-out	-	1,886
Deferred income taxes	2,675	1,845
Other liability	___1,113	____880
Total liabilities	_ 28,089	25,150
Stockholders’ equity:
Common stock	4	4
Treasury stock	(553)	(16)
Additional paid-in capital	48,853	48,074
Retained earnings	8,067	6,792
Accumulated other comprehensive income	____116	_____25
Total stockholders’ equity	56,487	54,879
Total liabilities & stockholders’ equity	$ 84,576	$ 80,029

BIOCLINICA, INC. AND SUBSIDIARIES Consolidated Statements of Cash Flows (In thousands) (unaudited)
	For the Six Months Ended
	6/30/11	6/30/10
Cash flows from operating activities:
Net income	1,275	1,114
Adjustments to reconcile net income to net cash provided by Operating activities:
Depreciation and amortization	1,767	1,588
Provision for deferred income taxes	539	285
Bad debt (recovery) expense	(15)	(9)
Stock based compensation expense	672	519
Accretion of acquisition earn-out	114	188
Changes in operating assets and liabilities:
Increase (decrease) in accounts receivable	(2,781)	147
Decrease (increase) in prepaid expenses and other current assets	410	(54)
(Increase) decrease in other assets	(2)	50
Increase in accounts payable	2,077	665
Decrease in accrued expenses and other current liabilities	(1,146)	(762)
Increase (decrease) in deferred revenue	133	(2,146)
Increase in other liabilities	_____234	_____248
Net cash provided by operating activities	$ 3,277	$ 1,833

Cash flows from investing activities:
Purchases of property and equipment	(351)	(2,001)
Capitalized software development costs	___(1,908)	___(2,815)
Net cash used in investing activities	$ (2,259)	$ (4,816)

Cash flows from financing activities:
Proceeds from sale/leaseback	514	-
Payments under equipment lease obligations	(88)	-
Purchase of treasury stock	(538)	-
Excess tax benefit related to stock options	19	30
Proceeds from exercise of stock options	87	22
Net cash provided by (used in) financing activities	$ (6)	$ 52

Effect of exchange rate changes on cash	64	(70)

Net increase (decrease) in cash and cash equivalents	1,077	(3,001)
Cash and cash equivalents at beginning of period	10,443	14,570
Cash and cash equivalents at end of period	$ 11,519	$ 11,569

BioClinica to Release Second Quarter 2011 Financial Results on August 3, 2011

Fri, 15 Jul 2011 10:05:45 -0400

– Conference Call to be Held at 11:00 a.m. EDT –

July 15, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a leading global provider of clinical trial management services will release its financial results for the second quarter ended June 30, 2011, on Wednesday, August 3, 2011.

	Download a printable version of this press release.
	Adobe Reader Required

Management of BioClinica, Inc. will host a conference call on the same day at 11:00 a.m. EDT. Those who wish to participate in the conference call may telephone 877-869-3847 from the U.S.; international callers may telephone 201-689-8261, approximately 15 minutes before the call. There will be a simultaneous webcast on the BioClinica website. A digital replay will be available by telephone approximately two hours after the call's completion for two weeks, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, Acct# 360; Replay ID# 375931. The replay will also be on the website under "Investor Relations" at www.bioclinica.com for two weeks.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Ted Kaminer | CFO of the Year, Medium Company

Mon, 11 Jul 2011 10:51:11 -0400

As posted on Philadelphiabusinessjournal.com

July 8, 2011

Ted Kaminer joined BioClinica Inc., a provider of technology-enabled services for clinical research based in Newtown, as its CFO in February 2003. Now executive vice president and CFO, Kaminer has helped drive the company's worldwide growth and expansion. During that period, revenues grew from $25 million to $75.2 million, while employment grew from 223 people to 475.

Kaminer oversees BioClinica's financial statements, audits, banking and financing relationships, investor relations and compliance with the Securities and Exchange Commission. He also manages the legal and human resource departments, contracts and proposals and regulatory and corporate administration.

During his first year as CFO, Kaminer initiated and closed a $10 million private placement. Since, he has successfully completed six acquisitions, without incurring any debt. Under his guidance, the company expanded its eClinical service and product offerings and entered a new area providing a suite of products.

Kaminer also actively supports and encourages all employees to support several charitable organizations and activities that BioClinica sponsors. These include the Penn State Dance Marathon, which raises money to find a cure for childhood cancers, the food bank Philabundance and the Greater Philadelphia Cares coat drive. As a rider in the MS-150, a fundraising cycling series for multiple sclerosis, Kaminer helped build a team of more than 25 riders that last year raised more than $15,000 to fight the disease.

Mark Weinstein, president and CEO of BioClinica, wrote in his nomination, "Since the day Ted arrived at BioClinica, he has been an invaluable resource to me and the company and has provided invaluable guidance to our sales and operational teams to enhance the cohesiveness that drives our success."

Alvert M. Piscopo, a partner at Price Waterhousecoopers, the auditor for BioClinica, wrote in his nomination, "Aside from having excellent accounting and finance skills, he is passionate about ensuring that the company has a rebust control structure in place — one that sets the right 'tone at the top' for the organization. He also does a great job of coaching his team by providing them with ample development opportunities to stretch their capabilities and add value to the company and its shareholders."

— Valerie Rubinsky

How did you arrive at your field? Applying the knowledge and skills developed in accounting and investment banking to become a CFO.

What have you done to contribute to your company's growth or profitability? During my tenure, we completed six acquisitions in the United States and Europe that expanded our medical imaging management capabilities into the cardiovascular and central nervous system areas and expanded our technology-enabled clinical trial offerings to include a full suite of eClinical solutions. During this time period the company grew from a marginally profitable business with a market cap of $28 million into a consistently profitable, global business with a market capitalization of $80 million and a strong balance sheet.

What have you done to strengthen your company's strategic position? During the last several years we expanded the company's suite of technology-enabled clinical trial services from our leading position in the medical image management solutions field to a full suite of best-in-class eClinical offerings that include electronic data capture; interactive voice and Web response; clinical supplies management and optimization; and clinical trial management solutions. This has increased our addressable market to more than $1 billion.

What have you done to safeguard your company's reputation? I'm responsible for the design, evaluation and supervision of our internal controls and procedures that govern our financial reporting.

What have you done to positively impact the community? I ride in the MS-150 bike race, along with the BioClinica team, to raise money for the National Multiple sclerosis Foundation.

What's the best career advice you ever got? Work hard, respect people and put the customer first.

If you weren't doing this, what would you want to be doing instead? Professional basketball.

Paragon Solutions and BioClinica Reveal Findings from First Clinical Trial Supplies Industry Forecasting Survey

Thu, 30 Jun 2011 14:00:33 -0400

As posted on Businesswire.com

Benchmark Survey underscores dissatisfaction with current processes in clinical supply chain industry and lack of supporting clinical trial supply management tools

CRANFORD, N.J.--(BUSINESS WIRE)--Paragon Solutions, an advisory consulting and systems integration firm, and BioClinica, Inc., (NASDAQ: BIOC) a leading global provider of clinical trial services, recently announced initial findings of a survey that provides industry benchmarks for processes surrounding the clinical trial supply management. In the first release of the findings, this ground-breaking analysis of the practices at some 25 companies to date correlates a significant level of dissatisfaction with current supplies forecasting and the technologies supporting the clinical trial process.

"Recognizing the importance of forecasting capabilities to the overall success and efficiency of the clinical supply chain, Paragon Solutions and BioClinica launched a survey to benchmark current industry practices and commercial solutions that support clinical supply forecasting"

Pharmaceutical, biotech and clinical research organization (CRO) companies are being tasked to reduce development costs for new products and streamline all R&D activities. As a result, today there is a higher level of scrutiny that has been put on drug development teams to create more efficient processes in their clinical trials.

"Recognizing the importance of forecasting capabilities to the overall success and efficiency of the clinical supply chain, Paragon Solutions and BioClinica launched a survey to benchmark current industry practices and commercial solutions that support clinical supply forecasting," said James O'Keefe, director, life sciences clinical optimization practice for Paragon Solutions.

The responses to date find that the majority of respondents do not currently use simulation and forecasting software, and that few tools are used to help reduce cost and increase the accuracy of clinical supplies forecasting. Half of the participants stated that they are not satisfied with how their company currently forecasts. Of the half that said they are pleased, nearly 75 percent are using tools of a greater sophistication than a spreadsheet.

"There is a significant opportunity for organizations to gain hard dollar and resource efficiencies through the use of more rigorous clinical trial forecasting and simulation processes," said Peter Benton, president of eClinical Solutions for BioClinica. "Indicators in the datasets show that the use of simulation technology, coupled with a process for ongoing re-forecasting and simulations of supply needs, can reduce the over-supply requirements by at least half. This provides a compelling case for implementing modeling and forecasting tools to support changes in clinical trial execution required to improve clinical trial supply management," he said.

The survey also uncovered a need to redefine the goals and priorities of the clinical supply chain departments. For example, supply forecasting for studies and sites is defined by sufficient availability and not accuracy. In fact, 43 percent of the respondents said they do not actively track, measure or report on supply overages. "Organizations will need to look beyond the mandate that focuses only on ensuring sufficient supply for studies and sites in order to more accurately forecast required supplies and increase efficiency," O'Keefe said.

The survey, which was initiated in April 2011, is comprised of 75 questions focused on the practices, processes and results as reported by direct participants. Additional respondents will have an opportunity to participate in the survey through 2011.

Clinical supply managers, study managers and clinical project managers from companies who have not yet participated in the benchmarking survey may complete the survey at http://clinicalsupplies.consultparagon.com/. Please direct any questions or comments to the following email: clinicalsupplies@consultparagon.com.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

About Paragon Solutions

Paragon Solutions is an advisory consulting and systems integration firm that specializes in enterprise information management to help clients leverage information assets for better business results. The company does this through its industry practices, solution accelerators and specialized technology competencies that help clients achieve operational efficiency, business scalability and regulatory compliance.

Paragon works with businesses that are focused in a few key industries — communications, financial services, healthcare, insurance and life sciences. The industry-focused practices work with Paragon's competency groups to address today's client concerns in Process Optimization, Information Management and Information Integration.

For more information, please visit the Paragon Web site at www.consultparagon.com, or call 1.800.462.5582.

Read the Complete Article

BioClinica Releases OnPoint CTMS to Meet Growing Market Demand

Mon, 20 Jun 2011 13:36:04 -0400

June 20, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced the release of BioClinica OnPoint CTMS and noted a surge in clinical trial management system (CTMS) demand. OnPoint is the new release of the CTMS platform that BioClinica acquired from TranSenda in 2010.

	Download a printable version of this press release.
	Adobe Reader Required

"A quiet transformation of clinical study architectures is occurring in the industry through the increased use of standard collaboration tools for clinical study management and regulatory document management," says Gartner Research Vice President Steve Lefebure. "Life science companies are seeking to leverage existing infrastructure, support collaboration, and create flexibility. Solutions that leverage both industry standard collaboration tools and office automation software while providing comprehensive clinical study management capabilities present significant advantages in this environment."

BioClinica OnPoint CTMS helps sponsors of clinical trials and CROs to efficiently access, share, and analyze operational trial data by leveraging the power and ease of use of the Microsoft® SharePoint standard collaboration and office automation tools. BioClinica's patent-pending data interchange technology eases the acquisition of operational data from multiple sources in real-time. OnPoint's tight integration with SharePoint enables users to interact with the system via Microsoft Office applications (Outlook, Excel, Word, etc.), speeding user adoption and compliance. Organizations find they can decrease their cost of ownership for large implementations using SharePoint’s proven scalability to manage millions of documents.

"We are experiencing extremely strong interest for OnPoint CTMS," said Peter Benton, President of eClinical Solutions for BioClinica. "So far in this quarter we have already received contract awards from four pharma and device companies that range from mid to large in size. The combination of features, value and fast implementation – augmented by OnPoint's out-of-the-box integration with SharePoint – is changing market perceptions of CTMS' utility and cost-effectiveness."

The new release of BioClinica OnPoint CTMS includes full support for the advanced features of SharePoint 2010. For organizations who desire to minimize infrastructure investment, BioClinica also offers hosting options for OnPoint. OnPoint has been selected by clinical trial sponsors and CROs after comprehensive market assessments and evaluations that have demonstrated not only the system's capabilities, but have also delivered high satisfaction ratings and a high level of user adoption.

Follow our Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica to Highlight New Trident IWR Release at DIA Meeting

Fri, 17 Jun 2011 21:33:56 -0400

– Exhibit Will Showcase eClinical Portfolio Interoperability –

June 16, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced a new release of Trident IWR, the latest addition to its best-in-class suite of eClinical applications. BioClinica will highlight Trident and other new product offerings at booth #1417, providing demonstrations of BioClinica’s integrated eClinical solutions, including:

	Download a printable version of this press release.
	Adobe Reader Required

Trident IWR Randomization to Express EDC
Express CRF Status to OnPoint CTMS and Clinical Payment Manager
Trident + Optimizer 360 Degree Clinical Supplies Forecasting and Management
Unified Reporting
Customer Portals
Microsoft Office Interoperability
Ad Hoc Reportin

BioClinica will also participate in an eClinical solutions showcase for the Microsoft platform, where they will demonstrate BioClinica’s open, standards-based architecture within the Microsoft Connected Life Sciences Framework guidance.

"Fewer drugs make it to market each year, yet many pharmaceutical companies continue to use the same development processes and procedures within an antiquated architecture," said Michael Naimoli, Worldwide Managing Director, Life Sciences, Microsoft "Microsoft and several partners, including BioClinica, worked together to develop a standard approach to information architecture across the industry that could enable companies to unlock valuable data, such as information that could lead to new therapies, and share that data among partners, customers and even regulatory agencies."

To see the benefits of this eClinical solution, please visit Microsoft at booth #1111 and BioClinica at booth #1417. The DIA 2011 Annual Meeting is being held in Chicago from June 20 – 23, with exhibits opened June 20 – 22.

Trident IWR provides clinical operations personnel an intuitive way to directly set up, monitor, and maintain randomization and supplies for their clinical trials. Trident's powerful parameter-driven study set-up eliminates programming for each new clinical trial and it configures both web and voice at the same time. This leads to greater efficiencies in starting new studies in a less costly manner and in a fraction of the time than other alternatives. This new release enhances Trident's capabilities for features such as managing temperature sensitive supplies and advanced supply pooling.

"Trident is truly changing the IWR landscape," said Mark Weinstein, CEO of BioClinica. "Clinical studies using Trident are typically developed and deployed within weeks. The combination of set-up speed and support for configuring even complex designs allows sponsors to make mid-study or last minute changes without affecting study timelines. This solution is literally changing what people can do with IWR/ IVR."

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica to Participate in Upcoming Clinical Trial Industry Events - June - July - 2011

Mon, 06 Jun 2011 13:54:33 -0400

BIOCLINICA, INC. TO PARTICIPATE IN UPCOMING CLINICAL TRIAL INDUSTRY EVENTS AND DEMONSTRATE ITS TECHNOLOGY–ENHANCED CAPABILITIES

NEWTOWN, PA, June 6, 2011 – BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that it will attend, participate in, and speak at the following industry conferences in June and July. BioClinica experts will discuss industry trends and also demonstrate its portfolio of technologies and solutions.

BioClinica to Participate in Upcoming Clinical Trial Industry Events: June - July 2011

Wed, 08 Jun 2011 15:31:07 -0400

BIOCLINICA, INC. TO PARTICIPATE IN UPCOMING CLINICAL TRIAL INDUSTRY EVENTS AND DEMONSTRATE ITS TECHNOLOGY–ENHANCED CAPABILITIES

June 6, 2011. NEWTOWN, PA – BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that it will attend, participate in, and speak at the following industry conferences in June and July. BioClinica experts will discuss industry trends and also demonstrate its portfolio of technologies and solutions.

	Download a printable version of this press release.
	Adobe Reader Required

ASCO Annual Meeting
June 3-7, 2011
Chicago, IL
Booth # 22082

With more than 20 years of experience, BioClinica has broad expertise in global oncology clinical trials. As a leading provider of technology-enhanced clinical trial management services, BioClinica will demonstrate the ways in which its experience and scientific resources help to ensure that clinical trial processes are efficient and well-managed.

5th Osteoarthritis Imaging Workshop
June 8 – 11, 2011
Salzburg, Austria

BioClinica will be a sponsor and participant at this important international workshop focused on scientific discussions about the clinical application and validation of imaging biomarkers related to Osteoarthritis research.

DIA 2011 47th Annual Meeting
June 19-23, 2011
Chicago, IL
Booth #1417

This meeting is the premier event for professionals involved in the discovery, development and life cycle management of pharmaceuticals, medical devices, and related products. On Tuesday, June 21, at 3:30 PM, Jonathan R. Andrus, MS, Vice President, Data and Study Operations for BioClinica, will chair a session entitled "Hot Topics in eClinical." This interactive showcase will discuss topics related to eClinical-based approaches for improving data quality, developing protocols, clinical trial planning and risk-based approaches, and how they can influence the role of monitoring.

AAICAD 2011
Alzheimer’s Association International Conference on Alzheimer’s Disease 2011
July 16-21, 2011
Paris, France
Booth #106

AAICAD is the world's leading forum on dementia research and provides leaders in the field a venue for learning and networking. BioClinica will demonstrate its advanced imaging capabilities and share information about its scientific resources in four poster presentations, including: "Whole-Brain and Ventricular Volume Change Measurement in Multicenter Clinical Trials: a Feasibility Study of Jacobian Integration using ADNI Data," and "High-Throughput and Accurate Segmentation of Lateral Ventricles Using Combined Single Atlas Propagation and Tissue Classification: Application to ADNI and IBSR Data."

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Business Journal names CFO of the Year finalists

Tue, 05 Jul 2011 11:16:04 -0400

As posted on Philadelphia Business Journal

Date: Friday, June 3, 2011, 11:51am EDT - Last Modified: Monday, June 6, 2011, 10:59am EDT

The Philadelphia Business Journal and Drexel University’s LeBow College of Business present the finalists in this year’s CFO of Year competition.

Finalists are listed below. The top winners in seven size categories will be revealed at an awards ceremony at the Crystal Tea Room inside the Wanamaker Building on July 7.

To qualify for the award, chief financial officers must work in the Business Journal’s eight counties of coverage (Philadelphia, Bucks, Delaware, Chester or Montgomery counties in Pennsylvania and Burlington, Camden and Gloucester counties in New Jersey) and have three consecutive years with their organization.

Nominations were sought from February through April.

A panel of independent judges selected the finalists in seven categories based on organization size. In addition, they awarded a Turnaround Achievement honor to a CFO who succeeded in a particularly tough assignment. The 2011 judges were: Dennis Cohen, member, Cozen O’Connor; Jeff Coursen, managing partner and chief operating officer, GPX Enterprises; Wayne Lorgus, partner, B2B CFO; Ellen Purdy, CFO, SDI Health (2010 award winner); George Tsetsekos, dean, Drexel University’s LeBow College of Business; Christopher Welde, CPA and analyst, ParenteBeard, and president of the Greater Philadelphia chapter of the PICPA.

In making their selections, judges looked for quantitative examples of how the CFO’s actions contributed to the organization’s growth, stability and reputation.

"All of Greater Philadelphia can be proud of these honorees," said George Tsetsekos, dean of the LeBow College of Business. "If these CFOs are indicative of the talent, professionalism and dedication of business leaders in our region, then we are in good hands."

Finalists

Richard Baron, Avid Radiopharmaceuticals Inc.

Larry Berran, iPipeline.

Arthur Chandler, Harleysville Group Inc.

Diane Corrigan, Hospital of the University of Pennsylvania.

Harold Earley, FXI Inc.

Tina Fiumenero, Vitae Pharmaceuticals.

Louis Gonczy, National Adoption Center/Adoption Center of Delaware.

John Hanson, Delaware River Port Authority.

Adam Kaliner, Power Home Remodeling Group.

Ted Kaminer, BioClinica Inc.

Brian McClintock, McGrath Systems.

Kevin McClure, NHS Human Services.

Dennis McGonigle, SEI.

Tonia McNeal, KenCrest.

Ashish Parikh, Hersha Hospitality Trust.

Edward Purdy, J.J. White Inc.

Joseph Trainor, University of the Sciences in Philadelphia.

David Whitwell, Ansaris.

Bill Zarrilli, Richardson.

Stephen Zarrilli, Safeguard Scientifics.

Read the Complete Article

BioClinica Announces Recommendations from ISS Group

Wed, 08 Jun 2011 16:07:40 -0400

BIOCLINICA ANNOUNCES RECOMMENDATIONS FROM ISS GROUP IN SUPPORT OF MATTERS TO BE CONSIDERED AT ITS ANNUAL MEETING

May 5, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, today announced that Institutional Shareholder Services (“ISS”, formerly RiskMetrics) has recommended that BioClinica’s shareholders vote in favor of all resolutions to be considered at the annual meeting (the “Meeting”) of the Company to be held on May 11, 2011, including for all directors and for the resolution to approve the Company’s Amended and Restated Shareholder Rights Plan. ISS is recognized as one of the leading independent proxy voting and corporate governance advisory firms. Its analyses and recommendations are relied upon by many major institutional investment firms, mutual funds and fiduciaries throughout North America. A copy of the Amended and Restated Shareholder Rights Plan was included with the Company's 2011 proxy statement and is also available on EDGAR at www.sec.gov.

	Download a printable version of this press release.
	Adobe Reader Required

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Additional Information:
This communication may be deemed to be solicitation material by the Company. The Company has filed its proxy statement on Schedule 14A and related materials with the Securities and Exchange Commission (the "SEC").

STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THE COMPANY'S PROXY STATEMENT RELATING TO THESE PROPOSALS, AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.

Stockholders will be able to obtain such documents free of charge through the website maintained by the SEC at www.sec.gov, or at the Company's website at www.bioclinica.com.

The Company and its directors and certain executive officers, may be deemed to be participants in the solicitation of proxies from the holders of the Company's common stock in respect of these proposals. Information about the directors and executive officers of the Company and their respective interests in the Company by security holdings or otherwise is set forth in its proxy statement relating to the 2011 annual meeting of stockholders, which was filed with the SEC on April 5, 2011.

BioClinica Announces Recommendations from ISS Group

Thu, 05 May 2011 11:39:20 -0400

NEWTOWN, PA, May 5, 2011 – BioClinica®, Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, today announced that Institutional Shareholder Services (“ISS”, formerly RiskMetrics) has recommended that BioClinica’s shareholders vote in favor of all resolutions to be considered at the annual meeting (the “Meeting”) of the Company to be held on May 11, 2011, including for all directors and for the resolution to approve the Company’s Amended and Restated Shareholder Rights Plan. ISS is recognized as one of the leading independent proxy voting and corporate governance advisory firms. Its analyses and recommendations are relied upon by many major institutional investment firms, mutual funds and fiduciaries throughout North America. A copy of the Amended and Restated Shareholder Rights Plan was included with the Company's 2011 proxy statement and is also available on EDGAR at www.sec.gov.

BioClinica Announces First Quarter 2011 Financial Results

Wed, 04 May 2011 10:56:42 -0400

-- Conference Call Today at 11:00 A.M. EDT --

NEWTOWN, PA, May 4, 2011 – BioClinica®, Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, today announced its financial results for the first quarter ended March 31, 2011.

BioClinica Announces First Quarter 2011 Financial Results

Wed, 08 Jun 2011 16:10:40 -0400

– Conference Call Today at 11:00 A.M. EDT –

May 4, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, today announced its financial results for the first quarter ended March 31, 2011.

	Download a printable version of this press release.
	Adobe Reader Required

Financial highlights for the quarter ended March 31, 2011 include:

Service revenues were $16.1 million as compared with $14.7 million for the same period 2010.
GAAP income from operations was $567,000, including a restructuring charge of $679,000, as compared with $1.2 million for the same period 2010.
GAAP net income was $351,000, or $0.02 per fully diluted share, including a restructuring charge of $426,000 or $0.03 per share, as compared with $711,000, or $0.05 per fully diluted share, for the same period 2010.
Non-GAAP income from operations was $1.8 million as compared with $1.7 million for the same period 2010.
Non-GAAP net income was $1.2 million, or $0.07 per fully diluted share, as compared to $1.1 million, or $0.07 per fully diluted share, for the same period 2010.
Backlog was $111.3 million as compared with $99.7 million for the same period 2010.

Mark L. Weinstein, President and Chief Executive Officer of BioClinica said, "Our results for the quarter reflect our successful acquisition and organic growth strategies. Over the past three years we have transformed BioClinica into an integrated provider of a full suite of technology-enhanced clinical trial solutions including Medical Imaging Solutions, EDC, IVR/IWR and CTMS. This quarter represents our 5th consecutive quarter of year-over-year growth in service revenue, reflecting the traction we have made in the industry as clients look to us to provide a broad array of services."

Highlights of our quarter include:

We signed seven new agreements for Trident IWR, our recently launched solution that enables clinical operations personnel to intuitively set up, monitor and maintain randomization supplies for clinical trials in a fraction of the time previously required. Trident’s ability to efficiently build and deploy complex trials without the need for programming, has been instrumental in our building of market share.
Millennium: The Takeda Oncology Company, signed an agreement for our new Enterprise Demand Aggregator (“EDA”) product. With this agreement, Millennium Pharmaceuticals becomes the first licensed customer of EDA, which greatly extends BioClinica Optimizer capabilities.
We experienced continuing interest in our clinical trial management system (“CTMS”) which leverages the power and ease of use of Microsoft SharePoint, and helps sponsors and CROs efficiently access, share and analyze operational clinical trial data in real-time.
We established a strategic partnership with Symbiance, a specialty contract research organization, who joins our expanding Certified Partner Program.
The implementation of our BioPACS™ imaging management system and release of our integrated BioREAD™ image review software continues to provide efficiencies to our entire organization. We have begun to realign our global resources to eliminate certain duplicate functions and reduce operating expenses. During the quarter we recorded a $679,000 or $0.03 per share charge, primarily comprised of severance and facility restructuring costs. The remaining $900,000 charge will be taken during the second and third quarters of 2011. The restructuring is expected to result in $1.2 million, or $0.05 per share, in annual operating expense savings.
During the first quarter, we repurchased 37,613 shares of BioClinica stock at an average price of $5.02 per share, as part of our stock repurchase program. At the end of the first quarter, there was $1,795,000 of funds remaining that may yet be used to repurchase shares under the plan that originally authorized purchases up to $2 million.
We ended the quarter with a strong balance sheet, including $10.2 million in cash and cash equivalents, positioning us well for future growth.

"We currently work with more than 200 pharmaceutical and medical device companies and CROs. These companies range in size from the largest to virtual and the projects transcend all phases of the clinical trial process. BioClinica is well-positioned to continue to win new clients and to expand our relationships with our current clients based on our comprehensive product portfolio, which includes medical image management, full service EDC including Data Management, IVR and CTMS." Mr. Weinstein added, "Our go-to-market strategy continues to be to provide our clients with a blend of services and technology that results in best-in-class clinical research solutions. We have made the investments necessary and will drive increased shareholder value by leveraging our global operational capabilities and sales and marketing organization as we provide these solutions."

Mr. Weinstein concluded, "Our $111.3 million backlog, an 11.6 percent increase from last year, is indicative of customer acceptance and our ability to convert our proposal pipeline into signed agreements. With this strong backlog, and our expectations to continue to strengthen our suite of services and expand our customer relationships, we remain on track to achieve our previously issued guidance. We are reiterating our expectations for full-year 2011 service revenue to be in the range of $66 to $70 million, our full-year GAAP EPS, including a restructuring charge of $0.06 per share, to be in the range of $0.16 to $0.21 per diluted share, and our full-year non-GAAP EPS to be in the range of $0.30 to $0.35 per diluted share."

Conference Call Information
Management of BioClinica, Inc. will host a conference call today at 11:00 a.m. EDT. Those who wish to participate in the conference call may telephone 877-869-3847 from the U.S.; international callers may telephone 201-689-8261, approximately 15 minutes before the call. There will be a simultaneous webcast on www.bioclinica.com. A digital replay will be available by telephone approximately two hours after the call’s completion for two weeks, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, Acct# 360; Replay ID# 371242. The replay will also be on the website under "Investor Relations" at www.bioclinica.com for two weeks.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

– FINANCIAL TABLES TO FOLLOW –

BIOCLINICA, INC. AND SUBSIDIARIES Consolidated Statements of Income (In thousands, except per share data) (unaudited)
	For the Three Months Ended
	03/31/11	03/31/10

Service revenues	16,144	14,746
Reimbursement revenues	3,521	3,358
Total revenues	$ 19,665	$ 18,104

Costs and expenses:
Cost of service revenues	10,557	8,951
Cost of reimbursement revenues	3,521	3,358
Sales & marketing expenses	1,860	2,210
General & admin. expenses	2,222	2,072
Amortization of intangible assets related to acquisitions	156	141
Mergers & acquisition related costs	103	205
Restructuring costs	679	-
Total cost and expenses	19,098	16,937
Income from operations	567	1,167
Interest income (expense) – net	(7)	3
Income before income tax	560	1,170
Income tax provision	209	459
Net income	351	711

Basic earnings per share	$ 0.02	$ 0.05
Weighted average number of shares - basic	15,652	14,545
Diluted earnings per share	$ 0.02	$ 0.05
Weighted average number of shares – diluted	16,417	15,382

BIOCLINICA, INC. AND SUBSIDIARIES GAAP to non-GAAP Reconciliation (1) (In thousands, except per share data) (unaudited)
	For the Three Months Ended
	03/31/11	03/31/10

GAAP income from operations	567	1,167
Stock-based compensation*	341	235
Amortization of intangible assets related to acquisitions	156	141
Merger & acquisition related costs	103	205
Restructuring charges	679	--
Non-GAAP income from operations	1,846	1,748


GAAP net income	351	711
Stock-based compensation, net of taxes	214	143
Amortization of intangible assets related to acquisitions, net of taxes	98	86
M&A related cost, net of taxes	65	125
Restructuring charges, net of taxes	426	--
Non-GAAP net income (2)	1,154	1,065
GAAP diluted earnings per share	$ 0.02	$ 0.05
Non-GAAP diluted earnings per share	$ 0.07	$ 0.07


*Stock based compensation included in total costs and expenses is as follows:
Cost of service revenues	245	160
Sales and marketing expenses	44	40
General and admin. expenses	52	35
Total stock-based compensation	341	235
(1) This table presents a reconciliation of GAAP to non-GAAP income from operations, net income and diluted earnings per share for the three months ended March 31, 2011 and 2010. The non-GAAP information excludes the impact of stock-based compensation, amortization of intangible assets related to acquisitions, restructuring charges and merger and acquisition costs. (2) The effective tax rate used for fiscal 2011 is 37.3%

BIOCLINICA, INC. AND SUBSIDIARIES Consolidated Balance Sheets (In thousands) (unaudited) ASSETS
	March 31, 2011	December 31, 2010
Current assets:
Cash and cash equivalents	$ 10,203	$ 10,443
Accounts receivable, net	12,644	11,866
Prepaid expenses and other current assets	2,622	2,501
Deferred income taxes	3,729	3,625
Total current assets	29,198	28,435
Property & equipment, net	14,564	14,029
Intangibles, net	2,275	2,430
Goodwill	34,302	34,302
Deferred income taxes	119	128
Other assets	727	705
Total assets	$ 81,185	$ 80,029
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$ 3,553	$ 1,983
Accrued expenses and other current liabilities	3,203	4,283
Deferred revenue	13,174	13,395
Current maturities of capital lease obligations	180	168
Total current liabilities	20,110	19,829
Long-term capital lease obligations	657	710
Long-term liability for acquisition earn-out	1,943	1,886
Deferred income taxes	1,990	1,845
Other liability	1,002	880
Total liabilities	25,702	25,150

Stockholders’ equity:
Common stock	4	4
Treasury stock	(204)	(16)
Additional paid-in capital	48,450	48,074
Retained earnings	7,143	6,792
Accumulated other comprehensive income	90	25
Total stockholders’ equity	55,483	54,879
Total liabilities & stockholders’ equity	$ 81,185	$ 80,029

BIOCLINICA, INC. AND SUBSIDIARIES Consolidated Statements of Cash Flows (In thousands) (unaudited)
	For the Three Months Ended
	03/31/11	03/31/10
Cash flows from operating activities:
Net income	351	711
Adjustments to reconcile net income to net cash provided by Operating activities:
Depreciation and amortization	1,030	728
Stock based compensation expense	341	235
Provision for deferred income taxes	41	163
Bad debt (recovery) expense	--	(9)
Accretion of acquisition earn-out	57	94
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	(778)	1,246
Increase in prepaid expenses and other current assets	(111)	(168)
(Increase) decrease in other assets	(22)	11
Increase (decrease) in accounts payable	1,435	(153)
Decrease in accrued expenses and other current liabilities	(1,077)	(624)
Decrease in deferred revenue	(221)	(1,218)
Increase in other liabilities	122	122
Net cash provided by operating activities	$ 1,168	$ 1,138
Cash flows from investing activities:
Purchases of property and equipment	(303)	(867)
Capitalized software development costs	(977)	(1,388)
Net cash used in investing activities	$ (1,280)	$ (2,255)

Cash flows from financing activities:
Payments under equipment lease obligations	(40)	--
Purchase of treasury stock	(188)	--
Proceeds from exercise of stock options	35	38
Excess tax benefit related to stock options	--	27
Net cash provided by (used in) financing activities	$ (193)	$ 65

Effect of exchange rate changes on cash	65	(49)

Net decrease in cash and cash equivalents	(240)	(1,101)
Cash and cash equivalents at beginning of period	10,443	14,570

Cash and cash equivalents at end of period	$ 10,203	$ 13,469

BioClinica to Participate in the Benchmark Company One-on-One Conference- May 12

Fri, 10 Jun 2011 10:31:16 -0400

May 2, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), today announced Mark L. Weinstein, President and Chief Executive Officer will be participating in The Benchmark Company, LLC One-on-One Conference on May 12, 2011 in Milwaukee, at The Pfister Hotel. At the Benchmark Conference, one-on-one meetings with investors are scheduled to be held throughout the day and Mr. Weinstein will be providing an overview of BioClinica, its business strategy and financial performance.

	Download a printable version of this press release.
	Adobe Reader Required

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica to Participate in the Benchmark Company One-on-One Conference- May 12

Mon, 02 May 2011 09:45:17 -0400

NEWTOWN, PA, May 2, 2011 – BioClinica®, Inc. (NASDAQ: BIOC) today announced Mark L. Weinstein, President and Chief Executive Officer will be participating in The Benchmark Company, LLC One-on-One Conference on May 12, 2011 in Milwaukee, at The Pfister Hotel. At the Benchmark Conference, one-on-one meetings with investors are scheduled to be held throughout the day and Mr. Weinstein will be providing an overview of BioClinica, its business strategy and financial performance.

BioClinica to Present at the 10th Annual JMP Securities Research Conference in San Francisco on May 9

Wed, 27 Apr 2011 10:03:21 -0400

NEWTOWN, PA, April 27, 2011 – BioClinica®, Inc. (NASDAQ: BIOC) today announced Mark L. Weinstein, President and Chief Executive Officer will be presenting at the Tenth Annual JMP Securities Research Conference in San Francisco on May 9, 2011 at 3:30 p.m. PDT.

BioClinica to Present at the 10th Annual JMP Securities Research Conference in San Francisco on May 9

Fri, 10 Jun 2011 11:10:40 -0400

April 27, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), today announced Mark L. Weinstein, President and Chief Executive Officer will be presenting at the Tenth Annual JMP Securities Research Conference in San Francisco on May 9, 2011 at 3:30 p.m. PDT.

	Download a printable version of this press release.
	Adobe Reader Required

Mr. Weinstein will be discussing an overview of BioClinica, its business strategy and financial performance.

The Company will provide a live webcast of the presentation. To access this presentation, listeners should go to the Investor Relations section of BioClinica's website, http://www.bioclinica.com/investor-events/, approximately 15 minutes prior to the event to register and download any necessary software.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica to Host First Quarter 2011 Financial Results Conference Call on May 4

Mon, 18 Apr 2011 09:35:32 -0400

- Conference Call to be Held at 11:00 a.m. EDT -
NEWTOWN, PA, April 18, 2011 – BioClinica®, Inc., (NASDAQ: BIOC), a leading global provider of clinical trial management services will release its financial results for the first quarter ended March 31, 2011, on Wednesday, May 4, 2011.

BioClinica to Host First Quarter 2011 Financial Results Conference Call on May 4

Fri, 10 Jun 2011 11:13:33 -0400

– Conference Call to be Held at 11:00 a.m. EDT –

April 18, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a leading global provider of clinical trial management services will release its financial results for the first quarter ended March 31, 2011, on Wednesday, May 4, 2011.

	Download a printable version of this press release.
	Adobe Reader Required

Management of BioClinica, Inc. will host a conference call on the same day at 11:00 a.m. EDT. Those who wish to participate in the conference call may telephone 877-869-3847 from the U.S.; international callers may telephone 201-689-8261, approximately 15 minutes before the call. There will be a simultaneous webcast on www.bioclinica.com. A digital replay will be available by telephone approximately two hours after the call’s completion for two weeks, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, Acct# 360; Replay ID# 371242. The replay will also be on the website under “Investor Relations” for two weeks.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica Inks Seven New Trident IWR Deals in First Quarter 2011

Fri, 10 Jun 2011 11:13:21 -0400

– Revolutionary Solution Increases Efficiency and Lowers Costs for Complex Global Trials –

April 7, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a leading provider of clinical trial management solutions, announced that Trident IWR (interactive web response) has been selected by seven new clients in the first quarter of 2011 to help build and deploy complex trials efficiently without the need for programming.

	Download a printable version of this press release.
	Adobe Reader Required

Trident IWR provides clinical operations personnel an intuitive way to directly set up, monitor, and maintain randomization and supplies for their clinical trials, in a less costly manner and in a fraction of the time than previous alternatives. Unlike other IWR systems, Trident IWR does not require programming for each new clinical trial and it configures both web and voice at the same time, leading to greater efficiencies in starting new studies.

In December of 2010, GlaxoSmithKline signed an agreement with BioClinica to standardize on the Trident IWR system, selecting the technology as a way to manage their global trials across Phase I-IV clinical trials.

"Since we launched Trident IWR in October 2010, BioClinica has received incredible industry-wide response," said Mark Weinstein, CEO of BioClinica. "With seven companies making the decision to standardize their complex trials with Trident IWR in just the first quarter of 2011 alone, we are happy to confirm that our best-in-class solution is successfully providing the efficiencies, cost savings and overall support needed by today's top pharmaceutical companies."

BioClinica Trident IWR has been selected by clinical trial sponsors and CROs after comprehensive market assessments and evaluations that have demonstrated not only the system's advanced capabilities, but also the flexibility and speed that allows this technology to be used in more trials than ever before.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica Inks Seven New Trident IWR Deals in First Quarter 2011

Thu, 07 Apr 2011 09:29:57 -0400

- Revolutionary Solution Increases Efficiency and Lowers Costs for Complex Global Trials -

NEWTOWN, PA, April 7, 2011 – BioClinica® Inc., (NASDAQ: BIOC), a leading provider of clinical trial management solutions, announced that Trident IWR (interactive web response) has been selected by seven new clients in the first quarter of 2011 to help build and deploy complex trials efficiently without the need for programming.

BioClinica to Participate in Upcoming Industry Events April - May 2011

Fri, 10 Jun 2011 11:18:52 -0400

April 5, 2011. NEWTOWN, PA – BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in and speak at several upcoming industry conferences in April and May. BioClinica experts will discuss industry trends and also demonstrate its suite of technologies and solutions.

	Download a printable version of this press release.
	Adobe Reader Required

Global Clinical Supplies Group
April 3-6, 2011Jacksonville, FL
Booth # 32

Global Clinical Supplies Group is a forum for open discussion to share knowledge and the industry’s best practices for clinical supply and related professionals. BioClinica will demonstrate its expanded suite of clinical trial services that maximize efficiency and manageability of the clinical trial process.

CDISC Interchange Europe 2011
April 13-14, 2011
Brussels, Belgium

Jennifer Price, Director, Clinical Solutions will present ‘Three Case Studies of Converting to CDISC (CDASH and SDTM) Standard’ on April 14, 2011 in the Emerging Device Standard track. CDISC is a global, open, multidisciplinary, non-profit organization that has established standards to support the acquisition, exchange, submission and archive of clinical research data and metadata.

63rd Annual American Academy of Neurology Meeting
April 9-16, 2011
Honolulu, HI
Booth # 960

BioClinica has extensive expertise in neurology clinical trials and as a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica will demonstrate how its systems and processes ensure that the end-to-end result is as efficient and expedient as possible. BioClinica will also present two posters, entitled “Accuracy and Reproducibility Assessment of FreeSurfer and Jacobian Integration Techniques” and “Labeling of Brain MRI Images Using Atlas Propagation and Classification-Based Nearest Neighbor Transform.”

ACRP (“Association of Clinical Research Professionals”) 2011 Global Conference
April 30-May, 3, 2011
Seattle, WA
Booth # 506

Jonathan Andrus, MS, CQA, CCDM, and VP of Data Management and Quality will run a workshop on “Data Manager and CRA Collaboration in an eClinical Environment – Working Together for Quality Data.” This workshop will focus on aspects that clinical research professionals from both the data management and clinical monitoring arena can do together. These practices lead to improved data quality and increase the speed and quality by which study databases can be reviewed, cleaned and locked. When these roles collaborate effectively, clinical trial management teams benefit from a more productive working relationship.

Outsourcing in Clinical Trials Europe
May 10-11, 2011
Zurich, Switzerland

Outsourcing in Clinical Trials Europe brings together major pharma and biotech manufacturers to debate potential solutions to complex challenges. As the industry struggles to meet the challenges associated with a difficult economic climate, making the best use of available resources is more important than ever. As a leading provider of outsourced clinical trial services, BioClinica will demonstrate its efficient and cost-effective suite of clinical trial solutions.

Annual European Congress of Rheumatology 2011 (EULAR)
May 25-28, 2011
London, England

Harris Ahmad, MD, Associate Medical Director of Medical Affairs, will present a poster entitled “Blinded Reads in Rheumatoid Arthritis Clinical Trials: Adjudication Rates for Varying Thresholds Based on Change Scores of Two Reader Utilizing X-Ray of Hand and Feet,” on Friday, May 27, 2011 at 11:45 a.m. – 1:30 p.m. The Annual European Congress of Rheumatology Congress will cover the broad spectrum of the rheumatic diseases and include state-of-the-art lectures, basic science and clinical symposia, abstract sessions, presentation and discussion of difficult cases, workshops and special interest group sessions.

BioClinica to Participate in Upcoming Industry Events April - May 2011

Tue, 05 Apr 2011 16:05:32 -0400

NEWTOWN, PA, April 5, 2011 – BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in and speak at several upcoming industry conferences in April and May. BioClinica experts will discuss industry trends and also demonstrate its suite of technologies and solutions.

BIOC - Millennium Pharmaceutical Becomes First Licensed Customer

Thu, 26 May 2011 15:36:05 -0400

MILLENNIUM PHARMACEUTICAL BECOMES FIRST LICENSED CUSTOMER FOR BIOCLINICA’S NEW ENTERPRISE DEMAND AGGREGATOR

-- Will Provide Enterprise-Wide Control for Clinical Supply Planning and Manufacturing --

NEWTOWN, PA, March 30, 2011 – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, has signed a technology agreement with Millennium: The Takeda Oncology Company, (Millennium) a leading biopharmaceutical company. This agreement makes Millennium the first customer for BioClinica’s new Enterprise Demand Aggregator (“EDA”) product offering. As part of the agreement BioClinica and Millennium will work in partnership to speed the release of the product which will advance Millennium’s clinical trial supply planning across all their global clinical trials.

Millennium Pharmaceutical Becomes First Licensed Customer

Fri, 10 Jun 2011 11:21:11 -0400

– Will Provide Enterprise-Wide Control for Clinical Supply Planning and Manufacturing –

March 30, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, has signed a technology agreement with Millennium: The Takeda Oncology Company, (Millennium) a leading biopharmaceutical company. This agreement makes Millennium the first customer for BioClinica's new Enterprise Demand Aggregator ("EDA") product offering. As part of the agreement BioClinica and Millennium will work in partnership to speed the release of the product which will advance Millennium’s clinical trial supply planning across all their global clinical trials.

	Download a printable version of this press release.
	Adobe Reader Required

Millennium has been using BioClinica Optimizer since 2007 to improve their ability to forecast clinical trial supplies and simulate their studies' requirements, resulting in greater efficiencies and cost benefits. "As we now want to improve and standardize our clinical supply forecasting and management across multiple trials with greater control than ever before, BioClinica's Enterprise Demand Aggregator application is a great addition for us," said Paul Skerker, Ph.D., Senior Director of Investigational Supply Operations for Millennium.

BioClinica's EDA will collect planning information from all of Millennium's Optimizer-simulated protocols in a central repository and provide an enterprise-wide view of the demand over time.

"BioClinica is introducing another eClinical offering which we anticipate will become an industry standard. We believe our rapidly expanding clinical and supply chain solutions are individually best-in-class, and the integration of our product offerings drive benefits unmatched in the industry," said Peter Benton, President of eClinical Solutions for BioClinica. "The pharmaceutical industry relies on technology innovation to drive necessary efficiencies. This partnership demonstrates Millennium’s commitment to innovate while also validating the benefits that BioClinica’s Optimizer technology provides."

Enterprise Demand Aggregator features will extend the capabilities of BioClinica Optimizer, including:

Macro level forecasts for studies in the early planning stages
Clinical supplies forecasts per study or program
Analysis of full enterprise demand against capacity
The ability to run "what if's" scenarios over time, and
Integration with other supply chain systems (MRP, ERP)

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About Millennium
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica CTMS Achieves Growing Market Acceptance

Fri, 10 Jun 2011 11:22:56 -0400

– Advanced Solution Increases Efficiency and Manageability for Clinical Studies –

March 23, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a leading provider of clinical trial management solutions, announced that BioClinica CTMS is experiencing a significant increase in client interest, customer wins and rapid startup success to help manage and streamline critical processes for upcoming clinical trials.

	Download a printable version of this press release.
	Adobe Reader Required

On Friday March 25, at the 4th Annual Forum on Clinical Trial Management Systems in Philadelphia, PA, Bob Leonard, Chief Information Officer, Harvard Clinical Research Institute will share case study examples of this transformation from Harvard Clinical Research Institute. Les Jordan, CTO, Life Sciences Industry Unit of Microsoft will present examples of how research team collaboration improves efficiencies through document sharing and consolidated reporting via SharePoint®. BioClinica will also demonstrate the CTMS offering at the upcoming Partnerships in Clinical Trials Conference, March 30 through April 1, in Phoenix, Arizona.

BioClinica CTMS helps sponsors of clinical trials and CROs to efficiently access, share, and analyze operational trial data in real-time, leveraging the power and ease of use of Microsoft SharePoint through a unique Office-Smart design. Making CTMS data available through SharePoint and leveraging SharePoint's seamless integration with the Microsoft Office Suite (Outlook, Excel, Word, etc.) benefits user adoption and compliance.

"The power of managing a clinical trial via Microsoft desktop applications is game changing. Clients are choosing BioClinica because they require a superior solution that helps them to enhance and streamline their clinical processes," said Peter Benton, President of eClinical Solutions for BioClinica. "They have determined that BioClinica CTMS technology and services best deliver the transparency, efficiency and ease of use that meets all of their needs. Faster implementations help our clients see results in a fraction of the time required for other alternatives. Tight integration with Microsoft SharePoint provides nearly limitless extensibility and flexibility for enterprises of any size."

BioClinica CTMS has been selected by clinical trial sponsors and CROs after comprehensive market assessments and evaluations that have demonstrated not only the system's capabilities, but have also delivered high satisfaction ratings and a high level of user adoption. When fully implemented, the clients' clinical trial managers have real-time access to a complete picture of their trials' status using the familiar interface and capabilities of SharePoint® and Microsoft® Office.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

BioClinica CTMS Achieves Growing Market Acceptance

Wed, 23 Mar 2011 10:39:47 -0400

- Advanced Solution Increases Efficiency and Manageability for Clinical Studies -

NEWTOWN, PA, March 23, 2011 – BioClinica® Inc., (NASDAQ: BIOC), a leading provider of clinical trial management solutions, announced that BioClinica CTMS is experiencing a significant increase in client interest, customer wins and rapid startup success to help manage and streamline critical processes for upcoming clinical trials.

Leading Companies to Participate in Clinical Supply Chain Benchmarking

Thu, 17 Feb 2011 09:35:17 -0500

- Study to Identify Industry Metrics for Clinical Supply Chain Management and Forecasting -

NEWTOWN, PA, February 17, 2011 – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial
management services, today announced the initiation of a study to assess current industry business challenges
and trends facing clinical supply chain management, including: study-drug forecasting, study design, and cost
reduction opportunities.

Leading Companies to Participate in Clinical Supply Chain Benchmarking

Fri, 10 Jun 2011 11:33:15 -0400

– Study to Identify Industry Metrics for Clinical Supply Chain Management and Forecasting –

February 17, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, today announced the initiation of a study to assess current industry business challenges and trends facing clinical supply chain management, including: study-drug forecasting, study design, and cost reduction opportunities. Participants will include experts in global study forecasting, drug pooling and adaptive trials from both large and small pharmaceutical companies. The results of this global study are expected to establish industry benchmarks for clinical supply chain metrics related to study design, forecasting, simulation, and optimization. Clinical sponsor organizations interested in participating in this research should visit http://clinicalsupplies.consultparagon.com/or email their request to: clinicalsupplies@consultparagon.com.

	Download a printable version of this press release.
	Adobe Reader Required

"Our industry currently lacks meaningful benchmarks for clinical trial supply chain management. BioClinica anticipates that these study findings will help to set new standards and approaches for trial sponsors and managers looking to find cost savings and create further efficiencies," said Peter Benton, President of eClinical Solutions for BioClinica. "There is an industry-wide need today for solutions partners to demonstrate quantifiable results for trial sponsors. At BioClinica, our goal is to not only offer best-in-class technologies, but also the insight and support to help forward our customers' business objectives."

BioClinica has partnered with a leading advisory and consulting firm, Paragon Solutions, to develop and conduct this research. Paragon Solutions has deep expertise in pharmaceutical supply chain optimization. The industry study is scheduled to begin immediately. It will include unique primary research including interviews and survey instruments. Upon completion, the results will be analyzed and used to create a forthcoming industry white paper.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About Paragon
Paragon Solutions is an advisory and technology consulting firm that specializes in enterprise information management to help clients leverage information assets for better business results. The company does this through its industry practices, solution accelerators and specialized technology competencies that help clients achieve operational efficiency, business scalability and regulatory compliance. Paragon’s Life Sciences practice addresses the needs of the pharmaceutical and biotechnology sectors. Our technology solutions are helping firms respond and capitalize on industry change driven by competition, consolidation, convergence and regulation.

For more information, please visit the Paragon Web site at www.consultparagon.com.
Martha Coacher
Paragon Computer Professionals, Inc.
(908) 653-3100
mcoacher@consultparagon.com

BioClinica Announces Fourth Quarter and Year End 2010 Financial Results

Wed, 16 Feb 2011 10:37:58 -0500

NEWTOWN, PA, February 16, 2011 – BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial services, today announced its financial results for the fourth quarter and year ended December 31, 2010.

BioClinica Announces Fourth Quarter and Year End 2010 Financial Results

Fri, 10 Jun 2011 11:37:46 -0400

– Conference Call Today at 11:00 A.M. EST –

February 16, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced its financial results for the fourth quarter and year ended December 31, 2010.

	Download a printable version of this press release.
	Adobe Reader Required

Financial highlights for the quarter ended December 31, 2010 include:

Service revenues were $16.5 million as compared with $14.9 million for the same period 2009.
GAAP income from operations was $1.2 million as compared with $1.6 million for same period 2009.
GAAP net income was $831,000, or $0.05 per fully diluted share, as compared with $943,000, or $0.06 per fully diluted share, for the same period 2009.
Non-GAAP income from operations was $1.8 million as compared with $2.0 million for the same period 2009.
Non-GAAP net income was $1.2 million, or $0.08 per fully diluted share, as compared to $1.2 million, or $0.08 per fully diluted share, for the same period 2009.
Backlog was $110.7 million as compared with $98.7 million for the same period 2009.

Financial highlights for the year ended December 31, 2010 include:

Service revenues were $62.7 million as compared with $57.4 million for the same period 2009.
GAAP income from operations was $4.3 million as compared with $4.7 million for the same period 2009.
GAAP net income was $2.8 million, or $0.17 per fully diluted share, as compared with $3.0 million, or $0.20 per fully diluted share, for the same period 2009.
Non-GAAP income from operations was $6.8 million as compared with $7.1 million for the same period 2009.
Non-GAAP net income was $4.3 million, or $0.27 per fully diluted share, as compared with $4.5 million, or $0.30 per fully diluted share, for the same period 2009.

Mark L. Weinstein, President and Chief Executive Officer of BioClinica said, "Our strategy to expand our suite of clinical trial solutions has proven to be successful in making us a stronger, more competitive company than ever before in our twenty-year history. During 2010 we fully integrated our acquisitions, strengthened our service offerings and launched several new products, while also making technological advances with respect to our existing services. This strategy is enabling us to attract new clients, both large and small, and to provide additional services to the more than 150 companies that we currently work with. There is a growing awareness that efficiencies need to be brought to the clinical trial process and we believe that with our current portfolio of products and services, we are very well-positioned to be part of the solution."

Some of the highlights of BioClinica's record year included:

New product launches —Trident, Optimizer, WebSend, WebView
Acquisition of TranSenda International
Several large multi-year enterprise agreements were signed with leading pharma companies, as described below:
- GlaxoSmithKline is deploying our Trident IWR product across its Phase I-IV clinical trials.
- Cephalon entered into an outsourcing agreement with us for clinical trial technology and support services to centralize and streamline its clinical data management operations.
- We entered into an agreement with another top 10 pharmaceutical client to utilize our BioClinica Optimizer product, making this the sixth of the top 10 pharma companies utilizing this product.
- We entered into an agreement with another top 10 pharmaceutical client to use our BioClinica Express product with full data management services on approximately 200 studies per year.
We hired a Chief Technology Officer and realigned our technology resources to ensure that all of our technology offerings are "best in class" and to ensure that we continue to move towards truly unified clinical trial solutions.

In December 2010 the Board of Directors authorized a share repurchase program of up to $2.0 million of the Company’s common stock over the next eighteen months. During December 2010, we purchased 3,500 shares at an average purchase price of $4.62 per share.

Mr. Weinstein continued, "The launch of our BioPacs imaging management system and the release of our integrated BioRead image review software further enhances the quality of our imaging corelab service offering and has enabled us to gain efficiencies by better utilizing resources across our U.S. and European operations. As a result, in 2011, we are realigning our global resources to eliminate certain duplicate functions and expect to take a total restructuring charge, primarily comprised of severance and facility restructuring costs, of $1.6 million, or $0.06 per fully diluted share, with half to be incurred in the first quarter and the other half to be incurred during the second and third quarters of this year. When fully implemented we expect annual operating savings achieved to benefit earnings per diluted share by $0.05 per share.

Mr. Weinstein concluded, "Our backlog of $110.7 million, which is a 12 percent increase from last year, is a good indicator that we are being successful in converting our strong proposal pipeline into contracts. With our strengthened suite of services, the increased level of proposal activity and our improved backlog, we expect our full year 2011 service revenue to be in the range of $66 to $70 million, our full-year GAAP EPS, including a restructuring charge of $0.06 per share, to be in the range of $0.16 to $0.21 per share, and our full-year non-GAAP EPS to be in the range of $0.30 to $0.35 per share."

Conference Call Information
Management of BioClinica, Inc. will host a conference today at 11:00 a.m. EDT. Those who wish to participate in the conference call may telephone 877-869-3847 from the U.S.; international callers may telephone 201-689-8261, approximately 15 minutes before the call. There will be a simultaneous webcast on www.bioclinica.com. A digital replay will be available by telephone approximately two hours after the call’s completion for two weeks, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, Acct# 360; Replay ID# 365105. The replay will also be on the website under "Investor Relations" at www.bioclinica.com for two weeks.

Non-GAAP Financial Information
BioClinica is providing information on 2010 and 2009 non-GAAP income from operations, non-GAAP net income and non-GAAP diluted earnings per share that exclude certain items, as well as the related income tax effects, because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. The non-GAAP information excludes, certain of which are recurring in nature, the impact of stock-based compensation, amortization of intangible assets related to acquisitions, restructuring charges and merger and acquisition costs. We believe the non-GAAP information provides supplemental information useful to investors in comparing our results of operations on a consistent basis from period to period. Management uses these non-GAAP measures in assessing our core operating performance and evaluating our ongoing business operations. These measures are not in accordance with, or an alternative for, generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. Therefore, the information may not necessarily be comparable to that of other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Investors are encouraged to review the reconciliations of these non-GAAP financial measures to the comparable GAAP results, which are included below in this press release.

– FINANCIAL TABLES TO FOLLOW –

BIOCLINICA, INC. AND SUBSIDIARIES Consolidated Statements of Income (In thousands, except per share data) (unaudited)
	For the Three Months Ended		For the Year Ended
	12/31/10	12/31/09	12/31/10	12/31/09

Service revenues	16,466	14,851	62,714	57,393
Reimbursement revenues	3,061	5,366	12,474	15,330
Total revenues	$ 19,527	$ 20,217	$ 75,188	$ 72,723

Costs and expenses:
Cost of service revenues	10,450	9,024	39,559	35,630
Cost of reimbursement revenues	3,061	5,366	12,474	15,330
Sales & marketing expenses	2,139	2,113	9,004	8,052
General & admin. expenses	2,389	1,871	8,446	7,414
Amortization of intangible assets related to acquisitions	165	145	638	489
Mergers & acquisition related costs	114	94	749	654
Restructuring costs	-	-	-	466
Total cost and expenses	18,318	18,613	70,870	68,035
Income from operations	1,209	1,604	4,318	4,688
Interest income (expense) – net	-	(3)	11	28
Income before income tax	1,209	1,601	4,329	4,716
Income tax provision	378	658	1,576	1,757
Net income	831	943	2,753	2,959

Basic earnings per share	$ 0.06	$ 0.07	$ 0.18	$ 0.21
Weighted average number of shares - basic	15,246	14,358	15,035	14,354
Diluted earnings per share	$ 0.05	$ 0.06	$ 0.17	$ 0.20
Weighted average number of shares – diluted	15,960	15,158	15,874	15,100

BIOCLINICA, INC. AND SUBSIDIARIES GAAP to non-GAAP Reconciliation (1) (In thousands, except per share data) (unaudited)
	For the Three Months Ended		For the Year Ended
	12/31/10	12/31/09	12/31/10	12/31/09

GAAP income from operations	1,209	1,604	4,318	4,688
Stock-based compensation*	289	161	1,080	760
Amortization of intangible assets related to acquisitions	165	145	638	489
Merger & acquisition related costs	114	94	749	654
Restructuring charges	--	--	--	466
Non-GAAP income from operations	1,777	2,004	6,785	7,057

GAAP net income	831	943	2,753	2,959
Stock-based compensation, net of taxes	199	91	687	480
Amortization of intangible assets related to acquisitions, net of taxes	113	85	406	309
M&A related cost, net of taxes	78	49	476	413
Restructuring charges, net of taxes	-	-	-	295
Non-GAAP net income (2)	1,221	1,168	4,322	4,456
GAAP diluted earnings per share	$ 0.05	$ 0.06	$ 0.17	$ 0.20
Non-GAAP diluted earnings per share	$ 0.08	$ 0.08	$ 0.27	$ 0.30

*Stock based compensation included in total costs and expenses is as follows:
Cost of service revenues	202	127	750	598
Sales and marketing expenses	41	17	171	81
General and admin. expenses	______46	______17	_____159	______81
Total stock-based compensation	_____289	_____161	__1,080	____760

(1) This table presents a reconciliation of GAAP to non-GAAP income from operations, net income and diluted earnings per share for the three months and year ended December 31, 2010 and 2009. The non-GAAP information excludes the impact of stock-based compensation, amortization of intangible assets related to acquisitions, restructuring charges and merger and acquisition costs. (2) The effective tax rate used for fiscal 2010 is 36.4%

BIOCLINICA, INC. AND SUBSIDIARIES Consolidated Balance Sheets (In thousands) (unaudited)
	December 31, 2010	December 31, 2009
Current assets:
Cash and cash equivalents	$ 10,443	$ 14,570
Accounts receivable, net	11,866	10,966
Prepaid expenses and other current assets	2,427	1,869
Deferred income taxes	4,011	3,370
Total current assets	28,747	30,775
Property & equipment, net	14,029	9,040
Intangibles, net	2,430	1,969
Goodwill	34,327	32,933
Deferred income taxes	1,358	-
Other assets	705	620
Total assets	$ 81,596	$ 75,337
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$ 1,983	$ 3,899
Accrued expenses and other current liabilities	4,283	4,134
Deferred revenue	13,395	14,256
Deferred income tax	411	-
Current liability for acquisition earn-out	-	1,184
Current maturities of capital lease obligations	168	-
Total current liabilities	20,240	23,473
Long-term liability for acquisition earn-out	1,886	1,657
Long-term maturities of capital lease Obligations	710	-
Deferred income taxes	3,001	1,167
Other liability	___880	___505
Total liabilities	26,717	26,802
Stockholders’ equity: Common stock	4	4
Treasury stock	(16)	-
Additional paid-in capital	48,074	43,104
Contingent consideration	-	1,309
Retained earnings	6,792	4,039
Accumulated other comprehensive income	_____25	_____79
Total stockholders’ equity	54,879	48,535
Total liabilities & stockholders’ equity	$ 81,596	$ 75,337

BIOCLINICA, INC. AND SUBSIDIARIES Consolidated Statements of Cash Flows (In thousands) (unaudited)
	For the Year Ended
	12/31/10	12/31/09
Cash flows from operating activities: Net income	2,753	2,959
Adjustments to reconcile net income to net cash provided by Operating activities:
Depreciation and amortization	3,452	2,711
Stock based compensation expense	1,080	760
Provision for deferred income taxes	348	336
Bad debt (recovery) expense	(9)	93
Accretion of acquisition earn-out	302	94
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	(682)	1,802
(Increase) decrease in prepaid expenses and other current assets	(620)	447
Decrease in other assets	(67)	(30)
(Decrease) increase in accounts payable	(1,848)	403
Decrease in accrued expenses and other current liabilities	(195)	(1,100)
Decrease in deferred revenue	(855)	(852)
Increase (decrease) in other liabilities	388	(71)
Net cash provided by operating activities	$ 4,047	$ 7,552

Cash flows from investing activities:
Purchases of property and equipment	(2,981)	(2,763)
Capitalized software development costs	(4,212)	(1,806)
Net cash paid for acquisitions, net of cash acquired	-	(3,144)
Net cash paid for acquisition earn-out	(1,257)	-
Net cash received for sale of assets of discontinued operations	--	500
Net cash used in investing activities	$ (8,450)	$ (7,213)

Cash flows from financing activities:
Proceeds from sale/leaseback	195	-
Payments under equipment lease obligations	-	(118)
Purchase of treasury stock	(15)	-
Proceeds from exercise of stock options	67	31
Excess tax benefit related to stock options	_____46	_____44
Net cash provided by (used in) financing activities	$ 293	$ (43)
Effect of exchange rate changes on cash	(17)	9
Net (decrease) increase in cash and cash equivalents	(4,127)	305
Cash and cash equivalents at beginning of period	14,570	14,265
Cash and cash equivalents at end of period	$ 10,443	$ 14,570

BioClinica, Inc. to Participate in Upcoming Industry Events and Demonstrate Global Technology–Enhanced Capabilities

Wed, 02 Feb 2011 10:12:52 -0500

NEWTOWN, PA, February 2, 2011 – BioClinica®, Inc. (NASDAQ: BIOC) today announced that members of its team will attend, participate in and speak at several upcoming industry conferences in February and March. BioClinica experts will discuss industry trends and also demonstrate its expanded suite of technology capabilities and offerings.

BioClinica, Inc. to Participate in Upcoming Industry Events and Demonstrate Global Technology–Enhanced Capabilities

Fri, 10 Jun 2011 11:40:16 -0400

February 2, 2011. NEWTOWN, PA – BioClinica®, Inc. (NASDAQ: BIOC), today announced that members of its team will attend, participate in and speak at several upcoming industry conferences in February and March. BioClinica experts will discuss industry trends and also demonstrate its expanded suite of technology capabilities and offerings.

	Download a printable version of this press release.
	Adobe Reader Required

February

3rd Annual Outsourcing in Clinical Trials West Coast
February 2-3, 2011
San Francisco, CA
Booth #35

Robert Eberle, a BioClinica consultant, will present on "Identifying the Cost of Conducting Clinical Research and the Use of Imaging Core Labs," on February 3, 2011 at 1:00 p.m., at this conference. Outsourcing in Clinical Trials brings together major pharma and biotech manufacturers to debate potential solutions to complex challenges. As the industry struggles to meet the challenges associated with a difficult economic climate, making the best use of available resources is more important than ever. As a leading provider of outsourced clinical trial services, BioClinica will demonstrate its efficient and cost-effective suite of clinical trial solutions.

12th Annual Clinical Trial Supply Europe
February 22-23, 2011
Barcelona, Spain
Booth #54

Ann Marie LaDue, Senior Project Manager, will speak on investigating the evolution of IVR (interactive voice response) systems through reflection on how they have changed over the last decade, on February 22, 2011 at 2:30 p.m. She will also discuss what to look for when evaluating IVR/IWR (interactive web response) technology, and how to choose a system that best matches an organization's requirements. This conference brings together clinical supply managers to uncover essential techniques to simplify supply for clinical trials.

March

2nd Annual Outsourcing in Clinical Trials East Coast
March 9-10, 2011
Somerset, NJ
Booth # 42

Robert Eberle, a BioClinica consultant, will present "Identifying the Cost of Conducting Clinical Research and the Use of Imaging Core Labs" on March 9, 2011 at 3:30 p.m., at this conference. Outsourcing in Clinical Trials brings together major pharma and biotech manufacturers to debate potential solutions to complex challenges. As the industry struggles to meet the challenges associated with a difficult economic climate, making the best use of available resources is more important than ever. As a leading provider of outsourced clinical trial services, BioClinica will demonstrate its efficient and cost-effective suite of clinical trial solutions.

Clinical Data Quality Summit
March 16-17, 2011
Sheraton National Hotel Arlington, VA

Jonathan Andrus, CCDM, Vice President, Data and Study Operations, will participate in a plenary session on Wednesday March 16, 2011 at 10:30 a.m. at this multidisciplinary summit that will review the case for quality in such areas as patient care, clinical records, protocol design, standards, e-clinical systems, policies and clinical data. Andrus will highlight foundational principles from a clinical, regulatory and data viewpoint.

4th Annual Forum on Clinical Trial Management Systems (CTMS)
March 24-25, 2011
Philadelphia, PA

BioClinica CTMS helps sponsors to leverage the power, familiarity and ubiquity of Microsoft Office and SharePoint platforms to deliver a real world window on clinical operations, across studies and across clinical technologies. Addressing this forum will be Les Jordan, CTO, Life Sciences Industry Unit at Microsoft, who will discuss how SharePoint helps companies to manage their clinical operational data by collecting more timely information and making more informed decisions. Bob Leonard of Harvard Clinical Research institute ("HCRI") will discuss the benefits HCRI has seen from surfacing clinical operations data through SharePoint via their BioClinica CTMS system, and how they use SharePoint to connect to Microsoft Office applications for improved data visibility and control.

Partnerships in Clinical Trials
March 30-April 1, 2011
Phoenix, AZ
Booth # 718

BioClinica will demonstrate its expanded suite of integrated clinical trial services that maximize efficiency and manageability of the clinical trial process at this clinical operations and outsourcing event which brings nearly 2,000 of the world's most strategic clinical trials executives to one location.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica to Release Fourth Quarter Year End 2010 Financial Results on February 16, 2011

Mon, 31 Jan 2011 09:19:32 -0500

NEWTOWN, PA, January 31, 2011 – BioClinica®, Inc., (NASDAQ: BIOC), a leading global provider of clinical trial management services will release its financial results for the fourth quarter and year ended December 31, 2010 on Wednesday, February 16, 2011.

BioClinica to Release Fourth Quarter Year End 2010 Financial Results on February 16, 2011

Fri, 10 Jun 2011 13:57:04 -0400

– Conference Call to be Held at 11:00 a.m. –

January 31, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a leading global provider of clinical trial management services will release its financial results for the fourth quarter and year ended December 31, 2010 on Wednesday, February 16, 2011.

	Download a printable version of this press release.
	Adobe Reader Required

Management of BioClinica, Inc. will host a conference call on the same day at 11:00 a.m. EDT. Those who wish to participate in the conference call may telephone 877-869-3847 from the U.S.; international callers may telephone 201-689-8261, approximately 15 minutes before the call. There will be a simultaneous webcast on www.bioclinica.com. A digital replay will be available by telephone approximately two hours after the call's completion for two weeks, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, Acct# 360; Replay ID# 365105. The replay will also be on the website under "Investor Relations" for two weeks.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica, Inc. to Present at the 21st Annual UBS Global Healthcare Services Conference

Fri, 21 Jan 2011 14:03:02 -0500

NEWTOWN, PA, January 21, 2011 – BioClinica®, Inc. (NASDAQ: BIOC) today announced Mark L. Weinstein, President and Chief Executive Officer will be presenting at the 21st Annual UBS Global Healthcare Services Conference in New York City on Monday, February 7, 2011 at 2:00 p.m. EST.

BioClinica, Inc. to Present at the 21st Annual UBS Global Healthcare Services Conference

Fri, 10 Jun 2011 13:58:25 -0400

January 21, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), today announced Mark L. Weinstein, President and Chief Executive Officer will be presenting at the 21st Annual UBS Global Healthcare Services Conference in New York City on Monday, February 7, 2011 at 2:00 p.m. EST.

	Download a printable version of this press release.
	Adobe Reader Required

Mr. Weinstein will be discussing an overview of BioClinica, its business strategy and financial performance.

The Company will provide a live audio broadcast of the presentation. To access this presentation, listeners should go to the Investor Relations section of the Company's website approximately 15 minutes prior to the event to register and download any necessary software.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica Partners with Symbiance

Fri, 10 Jun 2011 14:00:20 -0400

— New CRO Partner Joins BioClinica Certified Partner Program —

January 20, 2011. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of eClinical solutions, today announced it has established a strategic partnership with Symbiance Inc., a specialty contract research organization (CRO) based in Princeton Junction, New Jersey. Symbiance concentrates in therapeutic areas relevant to pharmaceutical and biotechnology companies with particular focus in oncology and CNS.

	Download a printable version of this press release.
	Adobe Reader Required

"With their therapeutic expertise and knowledge of the clinical trial space, Symbiance is an excellent partner for BioClinica’s eClinical offerings. I am confident in the added value this partnership will bring to our mutual clients," said Peter Benton, President of eClinical Solutions for BioClinica.

Symbiance began operations in 1990 to provide clear, precise and timely solutions for the data needs of clinical trial professionals. As a leading contract research organization with proven expertise in delivering innovative data solutions for pharmaceutical and biotechnology companies, Symbiance is committed to innovative and precise results that will allow clients to bring drugs to market quickly, accurately and cost effectively. Symbiance includes a clinical data management unit, biostatistical analysis, and SAS programming divisions supporting Phase I through IV clinical trials. For more information, please visit their company website.

"The BioClinica Certified Partner Program saw significant growth in 2010," continued Benton. "This growth has continued into the new year with the addition of experienced partners like Symbiance, allowing BioClinica to offer both a best in class product suite and added-value services for our clients. As many CROs seek partners that offer the highest level of technical expertise with global reach and support, they are finding that BioClinica fulfills their needs with the flexibility and capabilities that they require."

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica Partners with Symbiance

Thu, 20 Jan 2011 13:42:20 -0500

- New CRO Partner Joins BioClinica Certified Partner Program -

NEWTOWN, PA, January 20, 2011 – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced it has established a strategic partnership with Symbiance Inc., a specialty contract research organization (CRO) based in Princeton Junction, New Jersey.

GSK Picks BioClinica’s Randomization System

Tue, 05 Jul 2011 11:33:21 -0400

As posted on Clinpage.com

December 20, 2010

Inc. Research moved its headquarters to a new 120,000 sq. ft. location in Raleigh, North Carolina. Said CEO James Ogle in a press release: "This move better positions us to accommodate future growth of our clinical trials outsourcing services."

The FDA awarded a five-year data conversion contract to Octagon Research and ScenPro. The latter two companies will help the agency convert old FDA data to conform with Clinical Data Interchange Standards Consortium (CDISC) guidelines in an electronic age. Said Michael Gately, president of ScenPro: “We are excited about the opportunity to leverage our expertise to help the U.S. FDA broaden their use of data standards throughout the agency.” Here's a release.

Belgium's Unithink, an eclinical technology supplier, hired a new CEO: John Cline. The charismatic Cline was one of the earliest proponents of integrating multiple types of systems for clinical trials; he founded etrials (a precursor company within Merge) and guided it to a spot on the Inc. magazine 500.

That whole push to electronic health records, even with tens of billions of dollars in federal subsidies, is apparently not going so well, with adoption rates still below one quarter of all U.S. physicians. There are also isolated reports of serious medical errors and even deaths attributable to EHRs. Now federal regulators are considering the radical idea of regulating the systems. Any rules will probably take a few decades to implement, but vendors are still worried. "The policing of design by a third party or agency, however well intended, will likely stifle innovation and inhibit the growth and development of electronic health records in the future,” said Carl Dvorak, executive VP of Epic Systems. You read it here first. Electronic health records are a 21st century version of the metric system—a global norm that a fragmented, Balkanized U.S. won't be able to build correctly.

Although the recent financial reform legislation was almost entirely an empty act of theater, it did apparently contain one provision of concern to many industries. Congress increased the payouts to whistle blowers who help federal prosecutors sue large corporations. That's part of a trend of multinational employees talking to government officials instead of facing internal corporate retaliation. The phenomenon is especially common in pharma; the New England Journal of Medicine estimates the median recovery to be $3 million. James Wetta of AstraZeneca collected $45 million for spilling the beans on his firm; GSK's Cheryl Eckart will receive at least $96 million. In some cases, employees become whistle blowers at several firms sequentially, a testament to the sharp-eyed folks in the human resources department. Here are a newspaper story and a blog post.

GSK signed a multi-year contract to use a new randomization system from BioClinica. The technology will be used in all phases of research, a sign that GSK believes it should help in small and large trials alike. The new system will replace an in-house technology at GSK and allow nonprogrammer trial personnel to set up the randomizations for their own trials, without relying on overworked contractors specializing in the task. BioClinica's technology assigns patients to treatment arms and also manages drug supplies. (An October, 2010 ClinPage article is here.) The award was snatched from under the noses of a) the most established randomization supplier with a large British footprint and b) the largest U.S. database giant, which purchased multiple randomization solutions earlier this year. GSK was an early proponent of rolling out electronic data capture (EDC) in a big way, and it will be interesting to see if BioClinica's system heralds another, similar shift away from 1970s-era interactive voice response (IVR) systems and toward faster, more user-friendly software that still connects to the telephone network when needed. Here's a release.

Read the Complete Article.

BioClinica Announces Share Repurchase Program

Thu, 14 Jul 2011 13:25:41 -0400

December 17, 2010. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, announced that its Board of Directors has authorized a share repurchase program of up to $2.0 million of the Company's common stock over the next 18 months.

Repurchase under the program may be made through open market purchases or privately negotiated transactions in accordance with applicable federal securities laws, including Rule 10b-18. The timing of the repurchases and the exact number of shares of common stock to be purchased will be determined by the discretion of the Company's management, and will depend upon market conditions and other factors. The program will be funded using the Company's cash on hand and cash generated from operations. The program may be extended, suspended or discontinued at any time.

BioClinica currently has 15.2 million shares of common stock outstanding.

About BioClinica, Inc.

PDF - Adobe Reader Required | RSS | Media Contacts | Investor Contacts

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica Announces Share Repurchase Program

Fri, 17 Dec 2010 09:13:07 -0500

NEWTOWN, PA, December 17, 2010 – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, announced that its Board of Directors has authorized a share repurchase program of up to $2.0 million of the Company’s common stock over the next 18 months.

BIOC - GlaxoSmithKline Standardizes on BioClinica Trident IWR Solution

Thu, 16 Dec 2010 08:56:20 -0500

- Signs Multi-Year Agreement for Leading Global Trial Management Technology -

NEWTOWN, PA, December 16, 2010 – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, today announced that GlaxoSmithKline LLC ("GSK") has signed a multi-year enterprise technology agreement to deploy BioClinica's Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.

GlaxoSmithKline Standardizes on BioClinica Trident IWR Solution

Thu, 14 Jul 2011 13:07:33 -0400

— Signs Multi-Year Agreement for Leading Global Trial Management Technology —

September 8, 2010. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, today announced that GlaxoSmithKline LLC (“GSK”) has signed a multi-year enterprise technology agreement to deploy BioClinica's Trident IWR system across its Phase I-IV clinical trials.

"GSK had a requirement for a new IWR solution to enable internal staff to configure and manage highly complex IWR clinical studies, and we are pleased GSK chose Trident," said Mark Weinstein, CEO of BioClinica. "We look forward to supporting GSK so that they can successfully deploy and utilize our software in their upcoming studies."

Trident IWR's unique design provides clinical operations personnel with an intuitive way to directly set up, monitor, and maintain randomization and supplies for their clinical trials, in a fraction of the time previously required. Trident IWR system delivers rapid study setup without the need for programming, while simultaneously delivering world-class IVR system phone support through the same simplified configuration process.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.

PDF - Adobe Reader Required | RSS | Media Contacts | Investor Contacts

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica Celebrates 20th Anniversary

Tue, 14 Dec 2010 14:37:44 -0500

- Leading New Era of Integrated Clinical Trial Solutions Delivery -

NEWTOWN, PA, December 14, 2010 – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial
management services, is celebrating 20 years of experience, leadership and growth.

BioClinica Celebrates 20th Anniversary

Thu, 14 Jul 2011 13:37:36 -0400

— Leading New Era of Integrated Clinical Trial Solutions Delivery —

December 14, 2010. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial solutions, is celebrating 20 years of experience, leadership and growth.

Among the milestones BioClinica clinical trial solutions attained during its 20th anniversary year were:

Launched Trident IWR in October, a new IVR / IWR system that supports clinical trial randomization and supplies management with a unique interface that gives customers more flexibility and control by deploying complex trials in a fraction of the time previously required.
Launched a new release of Optimizer, the industry's premier clinical supply forecasting and management tool.
Acquired TranSenda International LLC in March for its clinical trial management software solution that creates efficiencies through interoperability with the Microsoft Office platform and SharePoint.
Launched a new version of WebSend used for tracking and electronically transferring medical images to the imaging core lab.
Launched Trial Blazers, an educational industry blog offering insight, resources and a listening ear to clinical trial sponsors, managers and partners within the industry.
Deployed BioPACs within the imaging core lab and a top pharmaceutical company which provides enhanced image workflow, query, inventory, site and project management tools to automate the process of evaluating images generated during a clinical trial.
Released a new state-of-the art version of BioREAD for performing more robust and efficient independent blinded reads of medical images collected during clinical trials.

Mark Weinstein, CEO of BioClinica said, "From the Company's origin as a developer and marketer of medical image management technologies, BioClinica has grown into a leading global provider of clinical trial solutions whose customers include all of the top ten pharmaceutical companies as well as two hundred other industry participants. Our twentieth anniversary in the clinical trial management services industry was marked with continued progress in terms of new product launches, new clients and a strategic acquisition, all of which have helped strengthen our product portfolio as we fulfill our mission of providing our customers with the best-in-class clinical trial management services. Last year's integration of our imaging core lab and eClinical services helped propel the company into what we believe will be a new decade of continued growth in our business and excellence in all that we do. We are proud of our accomplishments, and look forward to future decades of helping our customers with their complex clinical trial management needs."

You can follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.

PDF - Adobe Reader Required | RSS | Media Contacts | Investor Contacts

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BIOC - Kaizen Clinical Services Partners with BioClinica

Wed, 01 Dec 2010 09:08:56 -0500

- CRO Partnership Strengthens Certified eClinical Partner Program -

NEWTOWN, PA, December 1, 2010 – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, announced a strategic partnership with Kaizen Clinical Services, Inc., an oncologyfocused contract research organization (“CRO”).

Most Recently Posted News

A Case of Delayed Gratification

eClinical 2011: Remedies for the Clinical Trials Machine

Filling in the gaps as Big Pharma downsizes

Bucks software firm manages drug-trial data. And it's hiring.

BioClinica to Present at the UBS 22nd Annual Global Healthcare Services Conference

Harrison Clinical Research Selects BioClinica OnPoint CTMS

– Leading European CRO Chooses 'Flexible and Affordable' Clinical Trial Management (CTMS) Technology –

Bioclinica, Inc. to Sponsor and Lead Discussion at Key Clinical Trial Industry Events

– Experts Will Present Perspectives on Regulatory Guidances and Driving Clinical Trial Efficiency –

BioClinica to Host Fourth Quarter and Year-End 2011 Financial Results

– Conference Call to be Held at 11:00 a.m. EST –

Onconova Selects BioClinica Express Electronic Data Capture Solution

– Oncology Pioneer Leverages BioClinica EDC Technology to Accelerate Development of New Therapies –

BioClinica Announces Third Quarter 2011 Financial Results

– Conference Call Today at 11:00 A.M. EDT –

BIOCLINICA, INC. AND SUBSIDIARIES

BIOCLINICA, INC. AND SUBSIDIARIES

BIOCLINICA, INC. AND SUBSIDIARIES

BIOCLINICA, INC. AND SUBSIDIARIES

BioClinica Celebrates 10th Consecutive Year as a Deloitte Fast 50 Company

– Clinical Trials Solution Provider Attributes 87 Percent, Four-Year Total Revenue Increase to Solid Growth Strategy and Continued Employee Commitment –

Microsoft Technology Center to Host BioClinica User Conference

– Enterprise-Wide Cost Efficiencies and Trial Standardization Results Ahead of Targets –

BioClinica to Host Third Quarter 2011 Financial Results

– Conference Call Today at 11:00 A.M. EDT –

BioClinica Appoints Senior Medical Director - Dr. Andrzej Dzik-Jurasz

– New Position Expands Scientific Coverage for MRI Imaging and Oncology –

BioClinica Websend Effects Rapid Change in Clinical Trial Image Management

BioClinica Announces Major New Release of Express EDC Solution

– Interoperability with Trident IWR and OnPoint CTMS Redefines Suite –

Optinose Selects BioClinica Trident IWR, Optimizer and Imaging Core Lab Solutions

– Drug Delivery Company Selects BioClinica for Roster of Clinical Trials –

BioClinica to Showcase Knowledge and Expertise of Clinical Trial Management

– Company Thought Leaders to Present and Participate at Industry Meetings –

Vistakon Achieves Clinical Trial Efficiency Improvements with BioClinica

– Collaboration on EDC Processes and CDISC Standardization Cuts Costs and Reduces Study Launch Time –

BioClinica Reports Record Quarterly Service Revenues

– Non-GAAP Operating Income Increases 45.6% on an 8.7% Increase in Service Revenues –

– Conference Call Today at 11:00 A.M. EDT –

BIOCLINICA, INC. AND SUBSIDIARIES

BIOCLINICA, INC. AND SUBSIDIARIES

BIOCLINICA, INC. AND SUBSIDIARIES

BIOCLINICA, INC. AND SUBSIDIARIES

BioClinica to Release Second Quarter 2011 Financial Results on August 3, 2011

– Conference Call to be Held at 11:00 a.m. EDT –

Ted Kaminer | CFO of the Year, Medium Company

Paragon Solutions and BioClinica Reveal Findings from First Clinical Trial Supplies Industry Forecasting Survey

BioClinica Releases OnPoint CTMS to Meet Growing Market Demand

BioClinica to Highlight New Trident IWR Release at DIA Meeting

– Exhibit Will Showcase eClinical Portfolio Interoperability –

BioClinica to Participate in Upcoming Clinical Trial Industry Events - June - July - 2011

BioClinica to Participate in Upcoming Clinical Trial Industry Events: June - July 2011

BIOCLINICA, INC. TO PARTICIPATE IN UPCOMING CLINICAL TRIAL INDUSTRY EVENTS AND DEMONSTRATE ITS TECHNOLOGY–ENHANCED CAPABILITIES

Business Journal names CFO of the Year finalists

BioClinica Announces Recommendations from ISS Group

BIOCLINICA ANNOUNCES RECOMMENDATIONS FROM ISS GROUP IN SUPPORT OF MATTERS TO BE CONSIDERED AT ITS ANNUAL MEETING

BioClinica Announces Recommendations from ISS Group

BioClinica Announces First Quarter 2011 Financial Results

BioClinica Announces First Quarter 2011 Financial Results

– Conference Call Today at 11:00 A.M. EDT –

BIOCLINICA, INC. AND SUBSIDIARIES

BIOCLINICA, INC. AND SUBSIDIARIES

BIOCLINICA, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

BIOCLINICA, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

BioClinica to Participate in the Benchmark Company One-on-One Conference- May 12

BioClinica to Participate in the Benchmark Company One-on-One Conference- May 12

BioClinica to Present at the 10th Annual JMP Securities Research Conference in San Francisco on May 9

BioClinica to Present at the 10th Annual JMP Securities Research Conference in San Francisco on May 9

BioClinica to Host First Quarter 2011 Financial Results Conference Call on May 4

BioClinica to Host First Quarter 2011 Financial Results Conference Call on May 4

– Conference Call to be Held at 11:00 a.m. EDT –

BioClinica Inks Seven New Trident IWR Deals in First Quarter 2011

– Revolutionary Solution Increases Efficiency and Lowers Costs for Complex Global Trials –

BioClinica Inks Seven New Trident IWR Deals in First Quarter 2011

BioClinica to Participate in Upcoming Industry Events April - May 2011

BioClinica to Participate in Upcoming Industry Events April - May 2011

BIOC - Millennium Pharmaceutical Becomes First Licensed Customer